• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    hybrid light chain mouse. The present invention relates to genetically modified mice that express the variable ... (hv) sequences, including mice that express the hv sequences from an endogenous mouse light chain locus, mice that express the hv sequences from an endogenous mouse ... light chain site, and mice that express the hv ... sequences of a transgene or an episome in which the hv ... sequence is linked to a constant mouse sequence. the mice provided are a source of somatically mutated human variable sequences useful for making the antigen-binding proteins. compositions and methods for making antigen-binding proteins comprising human variable sequences, including human antibodies.
    公开号:BR112012032991B1
    申请号:R112012032991-0
    申请日:2011-06-22
    公开日:2021-08-10
    发明作者:Lynn MacDonald；Sean Stevens；Cagan Gurer；Andrew J. Murphy；Karolina A. Hosiawa
    申请人:Regeneron Pharmaceuticals, Inc；
    IPC主号:
    专利说明:

    [0001] The present invention relates to genetically modified mice that comprise a mouse or human lambda variable light chain sequence (VÀ) operably linked with a mouse or a human constant light chain region (À or kappa (k)) . Genetically engineered mice expressing epitope-binding proteins comprising an immunoglobulin light chain comprising a Variable domain derived from a human lambda variable gene segment (hVÀ), a human lambda J gene segment (hJÀ), and a mouse constant light chain (CL) domain. Genetically engineered mice, which comprise an immunoglobulin lambda (À) light chain variable nucleic acid sequence not rearranged in endogenous mouse light chain site. Mice capable of rearranging and expressing a mouse/human À light chain chimeric from an endogenous light chain site that comprises a replacement of all endogenous mouse light chain Variable region gene segments with one or more gene segments. hVA gene. and one or more hJÀ gene segments. The somatically mutated antibodies comprise the hVÀ domains and the mouse CL domains. BACKGROUND
    [0002] Mice that express antibodies that are fully human, or partially human and partially mouse, are known in the art. For example, transgenic mice expressing fully human antibodies from transgenes containing the human heavy chain and light chain immunoglobulin variable region genes have been reported. Genetically modified mice that make up a replacement of endogenous mouse heavy chain variable region (HCVR) gene segments and kappa light chain variable region (K) gene segments (LCVR) with human HCVR and LCVR gene segments and that produce chimeric antibodies with a chimeric human/mouse kappa chain are known as well.
    [0003] Antibody light chains are encoded via one of two separate sites: kappa (x) and lambda (À). Mouse antibody light chains are mainly of the K type. The ratio of K to À light chain utilization in humans is about 60:40, while in mice it is about 95:5. The biased use of k light chains in mice is reportedly supported in genetically modified mice capable of expressing fully or partially human antibodies. Thus, mice expressing fully or partially human antibodies appear to be limited in variable lambda (À) usage.
    [0004] There is a need in the art to generate lambda variable regions, whether mouse or human, for use in the manufacture of epitope binding proteins. There is a need in the art for mice that express fully or partially human antibodies, where mice exhibit an increased utilization of the variable lambda (V À).
    [0005] There is a need in the art for mice expressing fully or partially human antibodies, in which mice exhibit increased utilization of the variable À (VÀ). SUMMARY
    [0006] Genetically modified mice, embryos, cells, tissues, as well as nucleic acid constructs for modifying mice, and methods and compositions for making and using them, are provided. Mice and cells that generate lambda Variable regions (À) (human or non-human) in the context of a kappa (K) light chain are provided. Mice and cells that produce the human variable regions , in the context of a K or À light chain, for example, from the mouse endogenous light chain site, are also provided. Methods for preparing antibodies comprising the variable regions of lambda À are also provided. Methods to select heavy chains that express with lambda cognate variable regions are also provided.
    Human chimeric antigen binding proteins (eg antibodies) and the nucleic acids encoding them are provided which comprise the somatically mutated Variable regions, including antibodies which have light chains comprising a Variable domain derived from from a human VÀ and human JÀ gene segment fused to a mouse constant light chain domain.
    [0008] In one aspect, a mouse is provided that expresses the human variable region À sequence of a light chain that comprises a mouse constant region. In one aspect, a mouse is provided that expresses a human light chain variable region sequence À that comprises a constant region k. In one aspect, a mouse is provided that expresses from the mouse endogenous light chain locus of a light chain that comprises a human À variable region sequence. In one aspect, a mouse is provided that comprises a rearranged light chain gene that comprises a human variable sequence linked to a mouse constant region sequence and, in one embodiment, the mouse constant region sequence is a constant À sequence. , in one embodiment, the mouse constant region sequence is a constant K sequence.
    [0009] In one aspect, a genetically modified mouse is provided, wherein the mouse comprises an unrearranged human light chain variable gene segment (hVÀ) and a linker human À gene segment (hJÀ). In one embodiment, the unrearranged hVÀ and hJÀ are at a mouse light chain site. In one embodiment, the unrearranged hVÀ and unrearranged hJÀ are on a transgene and operably linked to a mouse or human constant region sequence. In one modality, the unrearranged hVÀ and unrearranged hJÀ are in an episome. In one embodiment, the mouse is capable of making an immunoglobulin that comprises a light chain that is derived from an hVÀ sequence and an unrearranged hJÀ sequence, and a mouse light chain constant region (CL) nucleic acid sequence. Methods and compositions for making and using the genetically modified mice are also provided.
    The antibodies that are provided comprise (a) a human heavy chain variable domain (hVÀ) fused to a constant mouse heavy chain region, and (b) a human hVÀ, fused to a mouse CL domain, including where one or more of the Variable domains are somatically mutated, for example, during selection of antibodies or immune cells from a mouse of the present invention. In one embodiment, unrearranged hJÀ and unrearranged hVÀ are operably linked to a human or mouse constant K region (CK). In one embodiment, unrearranged hJÀ and unrearranged hVÀ are operably linked to a human or mouse constant region À (Ck).
    [00011] In one aspect, a mouse that is provided comprises, in its germline, endogenous mouse light chain site, a human light chain À variable region sequence, wherein the human lambda variable region sequence is expressed in a light chain comprising a mouse immunoglobulin constant region gene sequence.
    [00012] In one embodiment, the endogenous mouse light chain site is an À site. In one embodiment, the endogenous mouse light chain site is a K site.
    [00013] In one embodiment, the mouse lacks an endogenous light chain variable sequence at the endogenous mouse light chain site.
    [00014] In one embodiment, all or substantially all of the endogenous mouse light chain Variable region gene segments are replaced with one or more human À variable region gene segments.
    [00015] In one embodiment, human light chain variable region sequence comprises a human J sequence. In one embodiment, the human JÀ sequence is selected from the group consisting of JÀ1, JÀ2, JÀ3, JÀ7, and a combination thereof.
    [00016] In one embodiment, the human light chain Variable region sequence À comprises a group A fragment of the human light chain site. In a specific embodiment, the group A fragment of the human À light chain site extends from hVÀ3 to 27 through hVÀ3 to 1.
    [00017] In one embodiment, the human À light chain Variable region sequence comprises a group B fragment of the human À light chain site. In a specific embodiment, the B-group fragment of the human light chain À site extends from hVÀ5 to 52 through hVÀ1 to 40.
    [00018] In one embodiment, the human À light chain variable region sequence comprises a group A gene fragment and a group B gene fragment. In one embodiment the human À light chain variable region sequence comprises at least one group A gene segment and at least one group B gene segment.
    [00019] In one embodiment, more than 10% of the naive mouse light chain repertoire is derived from at least two hVÀ gene segments, selected from 2 to 8, 2 to 23, 1 to 40, 5 to 45 , and 9 to 49. In one embodiment, more than 20% of the naive mouse light chain repertoire is derived from at least three gene segments selected from hVÀ 2 to 8, 2 to 23, 1 to 40, 5 to 45, and 9 to 49. In one embodiment, more than 30% of the naive mouse's light chain repertoire is derived from at least four gene segments selected from hVÀ 2 to 8, 2 to 23, 1 to 40, 5 to 45, and 9 to 49.
    [00020] In one aspect, a mouse is provided that expresses an immunoglobulin light chain that comprises a human Variable k sequence fused to a mouse constant region, where the mouse has a K to À utilization in the ratio of utilization of about of 1:1.
    [00021] In one embodiment, the immunoglobulin light chain is expressed from an endogenous mouse light chain site.
    [00022] In one aspect, a mouse is provided that comprises a light chain variable region sequence À (hVÀ), and at least one sequence J (J), contiguous with a mouse light chain constant region sequence K.
    [00023] In one embodiment, the mouse lacks a functional VK mouse gene segment and/or a JK mouse.
    [00024] In one modality, the VA is a human V Á (hVA), and the J is a human J Á ALREADY (hJA). In one embodiment, hVA and hJA are the unrearranged gene segments.
    [00025] In one embodiment, the mouse comprises a plurality of unrearranged hVA gene segments and at least one hJA gene segment. In a specific embodiment, the plurality of unrearranged hVA gene segments are at least 12 gene segments, at least 28 gene segments, or at least 40 gene segments.
    [00026] In one embodiment, at least one hJA gene segment is selected from the group consisting of JÁ1, JÁ2, JÁ3, JÁ7, and a combination thereof.
    [00027] In one embodiment, an endogenous mouse light chain site is eliminated in whole or in part.
    [00028] In one embodiment, the mouse K light chain constant region sequence is found in the endogenous mouse K light chain site.
    [00029] In one embodiment, about 10% to about 45% of mouse B cells express an antibody comprising a light chain comprising a human Á light chain Variable domain and a mouse k light chain constant domain ( CK).
    [00030] In one embodiment, the human Á variable domain is derived from a rearranged hVA/hJA sequence selected from the group consisting of 3 to 1/1, 3 to 1/7, 4 to 3/1, 4 to 3/7, 2 to 8/1, 3 to 9/1, 3 to 10/1, 3 to 10/3, 3 to 10/7, 2 to 14/1, 3 to 19/1, 2 to 23/ 1, 3 to 25/1, 1 to 40/1, 1 to 40/2, 1 to 40/3, 1 to 40/7, 7 to 43/1, 7 to 43/3, 1 to 44/1, 1 to 44/7, 5 to 45/1, 5 to 45/2, 5 to 45/7, 7 to 46/1, 7 to 46/2, 7 to 46/7, 9 to 49/1, 9 to 49/2, 9 to 49/7 and 1 to 51/1.
    [00031] In one embodiment, the mouse further comprises a human VK to JK intergenic region from a human K light chain site, in which the human Vk to J to 1c intergenic region is contiguous with the Vk sequence and the J sequence In a specific embodiment, the human Vk to Jk intergenic region is placed between the VÀ sequence and the J sequence.
    [00032] In one aspect, a mouse is provided that comprises (a) at least 12 to at least 40 human unrearranged light chain Variable region gene segments and at least one human JÀ gene segment in place of endogenous mouse light chain, (b) a human Vk to Jk intergenic sequence situated between the at least 12 to at least 40 human light chain Variable region gene segments to at least one human JÀ sequence; wherein the mouse expresses an antibody comprising a light chain comprising a human VÀ domain and a mouse CK domain.
    [00033] In one aspect, a mouse is provided that expresses an antibody comprising a light chain comprising a variable sequence À and a constant sequence K
    [00034] In one embodiment, the mouse exhibits a K utilization for À utilization in a ratio of about 1:1.
    [00035] In one embodiment, an immature B cell population obtained from mouse bone marrow exhibits a K utilization for À utilization of about 1:1.
    [00036] In one aspect, a genetically modified mouse is provided, wherein the mouse comprises an unrearranged immunoglobulin VÀ and JÀ gene segment operably linked to a mouse light chain gene comprising a mouse CL gene.
    [00037] In one embodiment, the VÀ and/or JÀ gene segments are human gene segments. In one embodiment, the V À and/or JÀ gene segments are mouse gene segments, and the CL is a CK mouse.
    [00038] In one embodiment, the endogenous mouse light chain site is a K light chain site. In one embodiment, the endogenous mouse light chain site is an À light chain site.
    [00039] In one embodiment, the unrearranged VÀ and JÀ gene segments meet at a site in the endogenous mouse light chain.
    [00040] In one embodiment, the unrearranged immunoglobulin VÀ and JÀ gene segments are on a transgene.
    [00041] In one embodiment, the mouse further comprises a replacement of one or more V, D, and/or J heavy chain gene segments with one or more human V, D, and/or J gene segments at the site of the heavy chain of an endogenous mouse immunoglobulin.
    [00042] In one embodiment, the mouse comprises a segment of the immunoglobulin VÀ and JÀ gene not rearranged in an endogenous K mouse at the site of the light chain that comprises a mouse CK gene.
    [00043] In one embodiment, the mouse comprises a rearranged human immunoglobulin À light chain variable gene segment (VA) and an gene segment spliced together (JÀÀ) into an endogenous mouse light chain locus that comprises a gene of mouse Ck.
    [00044] In one embodiment, the local light chain of the variable gene (the "VL site") comprises at least one human VÀ gene segment (hVÀ). In one embodiment, the VL site comprises at least one human JÀ gene segment (hJÀ). In another embodiment, the VL locus comprises up to four segments of the hJÀ gene. In one embodiment, the VL site comprises a contiguous sequence comprising human and human gene sequence K.
    [00045] In one embodiment, the light chain K Variables gene locus ("k site") comprises at least one human VÀ gene segment (hVÀ). In one embodiment, the K site comprises at least one human JÀ gene segment (hJÀ). In one embodiment, the K site comprises up to four segments of the hJÀ gene. In one embodiment, the K site comprises at least one hVÀ and at least one hJÀ and lacks or substantially lacks a functional gene segment VK region and does not or substantially lacks a functional JÀ region gene segment. In one embodiment, the mouse comprises the gene segment from the non-functional Vk region. In one embodiment, the mouse comprises no gene segment from the functional JK region.
    [00046] In one embodiment, the À light chain variable gene site (the "À site") comprises at least one hVÀ gene segment. In one embodiment, the À site comprises at least one human JÀ gene segment (hJÀ). In another embodiment, the À site comprises up to four segments of the hJÀ gene.
    [00047] In one embodiment, the VL site comprises a plurality of hVÀs. In one embodiment, the plurality of hVÀs is selected to result in the expression of an À light chain variable region repertoire that reflects about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% or more of the VA use observed in humans. In one embodiment, the VL site comprises hVÀ gene segments 1 to 40, 1 to 44, 2 to 8, 2 to 14, 3 to 21, and a combination thereof.
    [00048] In one embodiment, hVÀs include 3 to 1, 4 to 3, 2 to 8, 3 to 9, 3 to 10, 2 to 11, and 3 to 12. In a specific embodiment, the VL site comprises a sequence continuous from the human light chain À site extending from VK3 through 12 to VK3 through 1. In one embodiment, the VL site comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hVAs. In a specific embodiment, hVAs include 3 to 1.4 to 3, 2 to 8, 3 to 9, 3 to 10, 2 to 11, and 3 to 12. In a specific embodiment, the VL site comprises a continuous sequence of human À site extending from VÀv3 through 12 to VÀ3 through 1. In one embodiment, the VL site is at the endogenous K site. In a specific embodiment, the VL site is at the endogenous k site and the endogenous À light chain site is eliminated in part or completely. In one embodiment, the VL site is an endogenous À site. In a specific modality, the VL site is in the endogenous À locus and the endogenous K site is partially or totally eliminated.
    [00049] In one embodiment, the VL site comprises 13 to 28 or more hVÀs. In a specific modality, hVAs include 2 to 14, 3 to 16, 2 to 18, 3 to 19, 3 to 21, 3 to 22, 2 to 23, 3 to 25, and 3 to 27. In a specific modality, the K site comprises a contiguous human A site sequence extending from VÀ3 to 27 to VK3 to 1. In one embodiment, the VL site is at the endogenous K site. In a specific embodiment, the VL site is at the endogenous K endogenous site and the À light chain site is eliminated in part or completely. In another embodiment, the VL site is at the endogenous À site. In a specific modality, the endogenous VL site is at the À site and the endogenous K site is partially or totally eliminated.
    [00050] In one embodiment, the VL site comprises 29 to 40 hVÀs. In one embodiment, the K site comprises a human À contiguous sequence site extending from VK3 to 29 to VÀ 3 to 1, and a human À contiguous sequence locus extending from VÀ 0.5 to 52 for VÀ1 to 40. In a specific embodiment, all or substantially all of the sequence between hVÀ1 to 40 and hVÀ3 to 29 in the genetically modified mouse is essentially constituted by means of a human À sequence of approximately 959 per found in nature (for example , in the human population) downstream of the hVÀ±1 gene segment at 40 (downstream of the 3' end of the untranslated portion), a restriction enzyme site (e.g. P1 to SCEL), followed by means of a human À sequence of approximately 3,431 bp per amount of the hVÀ3 to 29 gene segment found in nature. In one embodiment, the VL site is at the K locus of the endogenous mouse. In a specific modality, the VL site is at the endogenous mouse K site and the endogenous mouse À site of the light chain is eliminated in part or completely. In another modality, the VL site is at the À site of the endogenous mouse. In a specific modality, the VL site is in the locus of the endogenous mouse and the K site of the endogenous mouse is partially or totally eliminated.
    [00051] In one embodiment, the VL site comprises at least one hJÀ. In one embodiment, the VL site comprises a plurality of hJÀs. In one embodiment, the VL site comprises at least 2, 3, 4, 5, 6, or 7 hJÀ. In a specific modality, the VL site comprises four hJÀ. In a specific modality, the four hJÀs are hJÀ1, hJÀ2, hJÀ3 and hJÀ7. In one embodiment, the VL site is a K site. In a specific embodiment, the VL site is at the endogenous K site and the endogenous À light chain site is eliminated in part or entirely. In one embodiment, the VL site comprises an hJÀ. In a specific modality, the hJÀ is hJÀ 1. In one modality, the VL site is at the endogenous K site. In a specific embodiment, the VL site is at the endogenous site and the K Site of the endogenous light chain is eliminated in part or completely. In another embodiment, the VL site is at the endogenous À site. In a specific modality, the VL site is in the endogenous À locus and the endogenous K site is partially or totally eliminated.
    [00052] In one embodiment, the VL site comprises at least one hVÀ, at least one hJÀ, and a mouse CK gene. In one embodiment, the VL site comprises at least one hVÀ, at least one hJÀ, and a mouse Ck gene. In a specific embodiment, the CÀ mouse CÀ gene is CÀ2. In a specific modality, the CÀ mouse CÀ gene is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, 96%, 97%, 98%, or at least minus 99% identical for CÀ2 mouse.
    [00053] In one embodiment, the mouse comprises a replacement at the endogenous mouse K site of endogenous mouse VK gene segments with one or more hVÀ gene segments, in which the hVÀ gene segments are operably linked to a region of the endogenous mouse CK gene, in such a way that the mouse rearranges the human VÀ gene segments and expresses a reverse chimeric immunoglobulin light chain that includes a human VÀ domain, and a Mouse Ck. In one embodiment, 90 to 100% of unrearranged mouse VÀ gene segments (are replaced with at least one unrearranged hVÀ gene segment. In a specific embodiment, all or substantially all of the endogenous mouse VK gene segments are replaced with at least one unrearranged HVÀ gene segment. In one embodiment, the replacement is with at least 12, at least 28, or at least 40 unrearranged hVÀ gene segments. In one embodiment, the replacement is with at least , seven unrearranged functional hVÀ gene segments, at least 16 unrearranged functional hVÀ gene segments, or at least 27 unrearranged functional hVÀ gene segments. In one embodiment, the mouse comprises a replacement of all gene segments from JÀ mouse with at least one unrearranged hJÀ gene segment. In one embodiment, at least one unrearranged hJÀ gene segment is selected from JÀ 1, JÀ 2, JÀ 3, JÀ 4, JÀ 5, JÀ 6, J2c7, and one of them. In a specific embodiment, the one or more segments of the hVÀ gene is selected from a 3 to 1, 4 to 3, 2 to 8, 3 to 9, 3 10, 2 to 11, 3 to 12, 2 to 14, 3 to 16, 2 to 18, 3 to 19.3 to 21, 3 to 22, 2 to 23, 3 to 25, 3 to 27, 1 to 40, 7 to 43, 1 to 44, 5 to 45, 7 to46 , 1 to 47, 5 to 48, 9 to 49, 1 to 50, 1 to 51, 5 to 52 a segment of the hVÀ gene, and a combination thereof. In a specific embodiment, at least one unrearranged hJÀ gene segment is selected from JÀ1, JÀ 2, JÀ3, JÀ7, and a combination thereof.
    [00054] In one embodiment, the mouse comprises a replacement of endogenous mouse VÀ gene segments at the endogenous mouse À site with one or more endogenous human VÀ gene segments at the mouse À site, where the hVÀ gene segments are operatively linked to a mouse CÀ region gene such that the mouse rearranges the hVÀ gene segments and expresses a reverse chimeric immunoglobulin light chain comprising an hVÀ domain and a mouse CÀ. In a specific embodiment, the mouse CÀ gene is CÀ2. In a specific modality, the CÀ mouse gene is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to that of the CÀ2 mouse. In one embodiment, 90 to 100% of unrearranged mouse VÀ gene segments are replaced with at least one unrearranged hVÀ gene segment. In a specific embodiment, all or substantially all endogenous mouse VÀ gene segments are replaced with at least one unrearranged hVÀ gene segment. In one embodiment, the replacement is with at least 12, at least 28, or at least 40 unrearranged hVÀ gene segments. In one embodiment, the replacement is with at least 7 functional hVÀ gene segments unrearranged, at least 16 functional hVÀ gene segments unrearranged, or at least 27 functional hVÀ gene segments unrearranged. In one embodiment, the mouse comprises a replacement of all mouse JÀ gene segments with at least one unrearranged hJÀ gene segment. In one embodiment, the at least one unrearranged hJÀ gene segment is selected from JÀ1, JÀ2, JÀ3, JÀ4, JÀ5, JÀ6, JÀ7, and a combination thereof. In a specific modality, one or more segments of the hVÀ gene is selected from a 3 to 1, 4 to 3, 2 to 8, 3 to 9, 3 to 10, 2 to 11, 3 to 12, 2 to 14, 3 to 16, 2 to 18, 3 to 19, 3 to 21, 3 to 22, 2 to 23, 3 to 25, 3 to 27.1 to 40, 7 to 43, 1 to 44, 5 to 45, 7 to 46, 1 to 47, 5 to 48, 9 to 49, 1 to 50, 1 to51, 5 to 52 an hVÀ gene segment, and a combination thereof. In a specific embodiment, at least one unrearranged hJÀ gene segment is selected from JÀ1, JÀ2, JÀ3, JÀ7, and a combination thereof.
    [00055] In one aspect, a genetically modified mouse is provided, which comprises a sequence of the human intergenic region Vk to Jk located at an endogenous mouse k light chain site.
    [00056] In one embodiment, the human Vk a Jk intergenic region sequence is in an endogenous mouse K light chain site that comprises a hVÀ gene segment, and hJÀ and the human VKJÀ intergenic region sequence is arranged between the hVA gene segments. and today. In a specific embodiment, the hVÀ and hJÀ gene segments are able to recombine to form a functional human à light chain variable domain in the mouse.
    [00057] In one embodiment, a mouse is provided that comprises a plurality of hVÀ's and one or more hJÀ's and the human intergenic region sequence Vk a Jk is disposed, relative to transcription, downstream of the proximal or most of the sequence. ' hVÀ and upstream or 5' of the first hJÀ sequence.
    [00058] In one embodiment, the human Vk to Jk intergenic region is a region located about 130 bp downstream or 3' of a human Vk4 to 1 gene segment, about 130 bp downstream of the 3' untranslated end of the human Vk4 to 1 gene segment, and extends up to about 600 bp upstream or 5' of a human JÀ 1 gene segment. In a specific embodiment, the human Vk to Jk intergenic region is about 22.8 kb of size. In one embodiment, the VK to JK intergenic region is about 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, or about 95% or more identical with a region human VK to JÀ intergenic extending from the end of the 3' untranslated end of a human Vk 4 to 1 gene segment to about 600 per upstream of a human JÀ1 gene segment. In one embodiment, the VK to Jk intergenic region comprises SEQ ID NO: 100. In a specific embodiment, the VK to Jk intergenic region comprises a functional fragment of SEQ ID NO: 100. In a specific embodiment, the VK to intergenic region ALREADY is SEQ ID NO: 100.
    [00059] In one aspect, a mouse, a cell mouse (eg a mouse in embryonic stem cells), a mouse embryo, and a mouse tissue are provided which comprise the said sequence of the human intergenic region VK to Jk , in which the intergenic region sequence is etopical. In a specific modality, the etopic sequence is placed at a site on the humanized endogenous mouse immunoglobulin.
    [00060] In one aspect, an isolated nucleic acid construct that is predicted to comprise the recited human VK to JK sequence intergenic region À. In one embodiment, the nucleic acid construct comprises target arms to target the sequence of the human VK to Jk intergenic region of a mouse light chain site. In a specific modality, the mouse light chain site is a K site. In a specific modality, the segmentation of target arms such as the human intergenic region VK to Jk from an endogenous modified mouse K site, where targeting is a position between a sequence of hVÀ, and a sequence of hJÀ
    [00061] In one aspect, a genetically modified mouse is provided, wherein the mouse comprises no more than two light chain alleles, wherein the light chain alleles comprise (a) an unrearranged human VÀ immunoglobulin, and a segment of JÀ gene, to an endogenous mouse light chain site comprising a Mouse CL gene, and, (b) an unrearranged immunoglobulin VL and an endogenous mouse light chain site JL gene segment comprising a Mouse CL gene Mouse.
    [00062] In one embodiment, the endogenous mouse light chain site is a K site. In another embodiment, the endogenous mouse light chain site is an À site.
    [00063] In one embodiment, no more than two light chain alleles are selected from one K allele and one À allele, two K alleles, and two À alleles. In a specific embodiment, one of the two light chain alleles is an À allele which comprises a CÀ2 gene.
    [00064] In one embodiment, the composite of a functional mouse light chain immunoglobulin site and a non-functional light chain site where the functional light chain site comprises an unrearranged human immunoglobulin VÀ and a JÀ gene segment in a endogenous mouse K light chain site that comprises a mouse CK gene.
    [00065] In one embodiment, the mouse comprises an immunoglobulin light chain functional site and a light chain non-functional site, wherein the light chain functional site comprises an unrearranged human immunoglobulin Vk and a gene segment at one site of the endogenous mouse JÀ light chain that comprises a mouse CÀ gene. In one embodiment, the CÀ gene is CÀ2. In a specific modality, the Mouse Ck gene is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to that of the CÀ2 mouse.
    [00066] In one embodiment, the mouse further comprises at least one immunoglobulin heavy chain allele. In one embodiment, the at least one heavy chain immunoglobulin allele comprises a human VÀ gene segment, a human DH gene segment, and an endogenous human gene segment in a mouse heavy chain JÀ site that comprises a gene from human heavy chain that expresses a human/mouse heavy chain. In a specific embodiment, the mouse is composed of two heavy chain immunoglobulin alleles, and the mouse expresses one human/mouse heavy chain.
    [00067] In one embodiment, the mouse comprises a first light chain allele that comprises an unrearranged hVÀ and an unrearranged hJÀ, to an endogenous mouse K site that comprises an endogenous CK gene, and a second light chain allele that comprises an unrearranged hVÀ and an unrearranged hJÀ, to an endogenous mouse K locus which comprises an endogenous CK gene. In a specific embodiment, the first and second light chain alleles are the only functional light chain alleles of the genetically modified mouse. In a specific modality, the mouse comprises a non-functional site. In one embodiment, the genetically engineered mouse does not express a light chain that comprises an À constant region.
    [00068] In one embodiment, the mouse comprises a first light chain allele comprising an unrearranged hVk and an unrearranged hJk, to an endogenous mouse K site comprising an endogenous CK gene, and a second light chain allele comprising an unrearranged hVÀ and an unrearranged hJÀ, to an endogenous mouse site that comprises an endogenous CÀ gene. In a specific embodiment, the first and second light chain alleles are the only functional light chain alleles of the genetically modified mouse. In one embodiment, the endogenous CÀ gene is CÀ2. In a specific modality, the CÀ mouse gene is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to that of the CÀ2 mouse.
    [00069] In one embodiment, the mouse is composed of six immunoglobulin alleles, wherein the first allele comprises a VÀ and JÀ immunoglobulin gene segment not rearranged into an endogenous mouse K site of the light chain that comprises a mouse gene Ck, the second comprises an unrearranged immunoglobulin VK and JK gene segment in an endogenous light chain mouse K site which comprises a Ck mouse gene, the third comprises an endogenous unrearranged immunoglobulin VÀ and JÀ gene segment in a mouse light chain À site comprising a mouse CÀ gene, every fourth and fifth independently comprises an unrearranged VH and DH and JH gene segment into an endogenous mouse heavy chain site comprising a mouse heavy chain gene. mouse, and the sixth comprises (a) an unrearranged immunoglobulin VÀ and JÀ gene segment from an endogenous mouse with a light chain À site comprising a gene from mouse CÁ, (b) an À site that is non-functional, or (c) a deletion of all or part of the À site.
    [00070] In one embodiment, the first allele comprises an unrearranged hVÀ and hJÀ. In one embodiment, the second allele comprises an unrearranged hVÀ and hJÀ. In one embodiment, the third comprises an unrearranged hVÀ and hJÀ allele. In one embodiment, every fourth and fifth independently comprises an unrearranged hVH and hDH and hJH. In one embodiment, the sixth allele comprises an endogenous mouse À site that is eliminated in whole or in part.
    [00071] In one embodiment, the mouse is composed of six immunoglobulin alleles, wherein the first allele comprises immunoglobulin VÀ and JÀ gene segment not rearranged in endogenous mouse light chain À site that comprises a mouse CÀ gene, the second comprises immunoglobulin VÀ and JÀ gene segment not rearranged into an endogenous mouse light chain À site which comprises a mouse Ck gene, the third comprises immunoglobulin VÀ and JÀ gene segment not rearranged from a K chain site endogenous mouse light comprising a mouse CK gene, every fourth and fifth independently comprises a VÀ and DH and JÀ gene segment not rearranged into an endogenous mouse heavy chain site comprising a mouse heavy chain gene, and the sixth comprises (a) a segment of the immunoglobulin VK and JÀ gene not rearranged into an endogenous mouse light chain K site that comprises a mouse gene CK, (b) a K site that is non-functional, or (c) a deletion of one or more elements from the K site.
    [00072] In one embodiment, the first allele comprises an unrearranged hVÀ and hJÀ gene segment. In one embodiment, the second allele comprises an unrearranged hVÀ and hJÀ gene segment. In one embodiment, the third allele comprises an unrearranged hVK and hJÀ gene segment. In one embodiment, every fourth and fifth independently comprises an unrearranged hVH and HDH and hJH gene segment. In one embodiment, the sixth allele comprises an endogenous mouse K site that is functionally silenced.
    [00073] In one embodiment, the genetically modified mouse comprises a B cell that comprises an antibody gene comprising a rearranged hVÀ domain functionally linked to a mouse CL domain. In one embodiment, the Mouse CL domain is selected from a mouse CK and a mouse CÀ domain. In a specific embodiment, the mouse CÀ domain is derived from a CÀ2 gene. In a specific embodiment, the CÀ domain mouse is derived from a CÀ domain, which is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% that of the mouse identical CÀ2.
    [00074] In one aspect, a mouse is genetically modified since it expresses VÀ in a CL region that is a CK. In one aspect, a genetically modified mouse is provided that expresses an hVÀ region in a CL selected from a human CK, a human CA, or a CK mouse. In one aspect, a genetically modified mouse that expresses an hVÀ region in a Ck mouse is provided.
    [00075] In one embodiment, about 10 to 50% of mouse splenocytes are B cells (ie, CD19 positive), or that about 9 to 28% express an immunoglobulin light chain comprising hVÀ domain fused to a domain of mouse Ck.
    [00076] In a specific modality, about 23 to 34% of mouse splenocytes are B cells (ie, CD19 positive), or that about 9 to 11% express an immunoglobulin light chain that comprises a fused hVÀ domain to a domain of Mouse Ck.
    [00077] In a specific embodiment, about 19 to 31% of mouse splenocytes are B cells (ie, CD19 positive), or that about 9 to 17% express an immunoglobulin light chain comprising an hVÀ domain fused to a domain of Mouse Ck.
    [00078] In a specific modality, about 21 to 38% of mouse splenocytes are B Cells (ie, CD19 positive), or that about 24 to 27% express an immunoglobulin light chain that comprises a fused hVÀ domain to a domain of Mouse Ck.
    [00079] In a specific embodiment, about 10 to 14% of mouse splenocytes are B Cells (ie, CD19 positive), or that about 9 to 13% express an immunoglobulin light chain that comprises a fused hVÀ domain to a domain of Mouse Ck.
    [00080] In a specific embodiment, about 31 to 48% of mouse splenocytes are B Cells (ie, CD19 positive), or that about 15 to 21% express an immunoglobulin light chain that comprises a fused domain hVÀ to a domain of Mouse Ck. In a specific embodiment, about 30 to 38% of mouse splenocytes are B cells (ie, CD19 positive), of which about 33 to 48% express an immunoglobulin light chain comprising an hVÀ domain fused to a domain of Mouse Ck.
    [00081] In one embodiment, about 52 to 70% of mouse bone marrow are B cells (CD19 positive), or that about 31 to 47% of immature B cells (ie, CD19 positive/B220 intermediate positive/IgM positive) of expressing an immunoglobulin light chain comprising an hVÀ domain fused to a Mouse Ck domain.
    [00082] In one embodiment, about 60% of mouse bone marrow are B cells (ie, CD19 positive), or that about 38.3% of immature B cells (ie, CD19 positive/intermediate B220 positive/ positive IgM) express an immunoglobulin light chain comprising an hVÀ domain fused to a Mouse Ck domain. In one embodiment, the mouse expresses an antibody comprising a light chain comprising a Variable domain derived from a human V and human J gene segment, and a constant domain derived from a mouse constant region gene. In one embodiment, the mouse constant region gene is a CK gene. In another embodiment, the mouse constant region gene is a CÀ gene. In a specific embodiment, the CÀ region is CÀ2. In a specific embodiment, the CÀ mouse gene is derived from a Ck gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse CÀ2. In a specific embodiment, the antibody further comprises a heavy chain which comprises a Variable domain derived from a human V gene segment, a human D and a human J, and a heavy chain constant domain derived from a constant chain region gene. mouse heavy. In one embodiment, the constant region mouse heavy chain gene comprises a hinge of the CH2 to CH3 sequence of a heavy chain constant domain. In another embodiment, the constant region mouse heavy chain gene comprises the hinge of the CH1 to CH2 to CH3 sequence of a heavy chain constant domain. In another embodiment, the mouse heavy chain constant region gene comprises a sequence from CH1 to CH2 to CH3 to CH4 of a heavy chain constant domain. In another embodiment, the mouse heavy chain constant region gene comprises a CH2 to CH3 to CH4 sequence of a heavy chain constant domain.
    [00083] In one embodiment, the mouse expresses an antibody comprising a light chain comprising a human reorganized sequence VÀ to JÀ, and a mouse sequence CK. In one embodiment, the rearranged human VÀ to JÀ sequence is derived from a rearrangement of selected gene segments from an hVÀ 3 to 1, 4 to 3, 2 to 8, 3 to 9, 3 to 10, 2 to 14, 3 to 19, 2 to 23, 3 to 25, 1 to 40, 7 to 43, 1 to 44, 5 to 45, 7 to 46, 1 to 47, 9 to 49, and a gene segment 1 to 51. In one modality , the rearranged human VÀ to JÀ sequence, is derived from rearranged hJÀ gene segments, selected from JÀL, JÀ 2, JÀS, and JÀ 7 gene segment.
    [00084] In one embodiment, the mouse expresses an antibody comprising a light chain comprising a rearranged immunoglobulin À light chain variable region comprising a human sequence V /JÀ, selected from 3 to 1/1, 3 to 1/7, 4 to 3/1, 4 to 3/7, 2 to 8/1, 3 to 9/1, 3 to 10/1, 3 to 10/3, 3 to 10/7, 2 to 14/ 1, 3 to 19/1, 2 to 23/1, 3 to 25/1, 1 to 40/1, 1 to 40/2, 1 to 40/3, 1 to 40/7, 7 to 43/1, 7 to 43/3, 1 to 44/1, 1 to 44/7, 5 to 45/1, 5 to 45/2, 5 to 45/7, 7 to 46/1, 7 to 46/2, 7 to 46/7, 9 to 49/1, 9 to 49/2, 9 to 49/7 and 1 to 51/1. In a specific embodiment, the B cell expresses an antibody comprising a heavy chain human immunoglobulin Variable domain fused to a constant mouse heavy chain domain, and a human immunoglobulin light chain k Variable domain fused to a chain domain slight mouse constant K.
    [00085] In one aspect, there is provided a mouse that expresses an antibody that comprises (a) a heavy chain that comprises a heavy chain Variable domain derived from an unrearranged human heavy chain region gene segment, wherein the Variable domain The heavy chain is fused to a constant mouse heavy chain (CH) region, and (b) a light chain comprising a light chain Variable domain derived from an hVÀ and an unrearranged hJÀ, where the Variable domain of the chain light is fused with a Mouse CL region.
    [00086] In one embodiment, the mouse comprises (i) a heavy chain site comprising a replacement of all or substantially all functional gene segments from endogenous mouse V, D and J with all or substantially all functional gene segments human V, D, J and, a mouse CH gene, (ii) a light chain first K site comprising a substitution of all or substantially all of the functional endogenous mouse VK and JÀ gene segments, substantially all, or a plurality of functional hVÀ and hJÀ gene segments, and a mouse CK gene, (iii) a second light chain K site comprising a replacement of all or substantially all functional endogenous mouse VK and JK gene segments with substantially all , or a plurality of functional mouse hVk and hJk gene segments of the CK gene. In one embodiment, the mouse does not express an antibody that comprises a CA region. In one embodiment, the mouse comprises a deletion of a CÀ and/or VÀ gene segment and/or a JÀ gene. In one embodiment, the non-functional mouse comprises an À light chain site. In a specific embodiment, the À light chain site is deleted, in whole or in part.
    [00087] In one embodiment, the mouse comprises (i) a heavy chain site comprising a replacement of all or substantially all functional gene segments from endogenous mouse V, D and J with all or substantially all functional gene segments V, D and J, a mouse CH gene, (ii) a light chain first K site comprising a replacement of all or substantially all functional gene segments V, D and J with all, substantially all, or a plurality of functional hVÀ and hJÀ gene segments and a mouse CÀ gene, (iii) a second light chain K site comprising a replacement of all or substantially all functional endogenous mouse VÀ and JÀ gene segments with all, substantially all, or a plurality of functional hVÀ and hJÀ gene segments, and a mouse CÀ gene. In a specific embodiment, the mouse CÀ gene is CÀ2. In a specific embodiment, the CÀ mouse gene is derived from a CÀ gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to from the CÀ2 mouse.
    [00088] In one embodiment, the mouse comprises a deletion of a CK gene segment and/or a VK gene and/or a JÀ gene. In one embodiment, the non-functional mouse comprises a K light chain site.
    [00089] In one aspect, a genetically modified mouse that expresses an antibody is provided, in which more than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 60%, greater than 70%, greater than 80%, or greater than 90% of the total IgG antibody produced by the mouse comprises a Variable k domain derivative, and in which the mouse expresses the antibodies which comprise a derived Variable K domain fused to a Mouse Ck region. In specific modalities, about 15 to 40%, 20 to 40%, 25 to 40%, 30 to 40% or 35 to 40% of the total antibodies produced by the mouse comprise a Variable k domain derivative.
    [00090] In one embodiment, the Variable domain of an À derivative is derived from an hVÀ and an hJÀ. In one embodiment, the Variable domain of a k derivative is a light chain that comprises a mouse CK region. In a specific embodiment, the Variable region of a k derivative is a light chain comprising a mouse CA region. In another specific embodiment, the region is a Ck CÀ2 region. In one embodiment, the Variable domain of derivative K is derived from hVÀ and hJÀ, and in a specific embodiment it is a light chain comprising a mouse CK region.
    [00091] In one aspect, an isolated DNA construct is provided that comprises an upstream homology arm and a downstream homology arm, wherein the upstream and downstream homology arms segment a construct from a mouse Site K, and the construct comprises an unrearranged functional hVÀ segment and an unrearranged functional hJÀ segment, and a selection or marker sequence.
    [00092] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' with respect to the direction of transcription, a targeting arm for an upstream targeting sequence of mouse V À 2, a cassette 5' and 3' flanked selection cassette with recombinase recognition sites, and a targeting arm to target a mouse JÀ 2 À 3' sequence. In one embodiment, the selection cassette is a Frt' ed Hyg cassette. - TK. In one embodiment, the 3' end of the targeting arm comprises mouse CÀ2, JÀ4, CÀ4, and enhancer mouse 2.4.
    [00093] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' with respect to the direction of transcription, a targeting arm to the mouse target site À5' with respect to VÀ1, a cassette selection panel flanked in 5' and 3' with recombinase recognition sites, and in 3' segmentation arm 3' to target an À3' mouse sequence relative to the CK1 mouse. In one embodiment, the selection cassette is a neomycin loxed cassette. In one embodiment, the 3' end of the segmentation arm comprises the mouse À 3' enhancer and mouse À 3' enhancer 3.1.
    [00094] In one aspect, an isolated DNA construct is provided, which comprises from 5' to 3' with respect to the direction of transcription, a targeting arm to the mouse target site of 5' with respect to VÀ2, a 5' and 3' flanked selection cassette with recombinase recognition sites and 3' of the targeting arm to target a sequence from mouse À3' to mouse JÀ2 and 5' to mouse CÀ2. In one embodiment, the selection cassette is a Frt’ ed -TK hygromycin cassette. In one embodiment, the 3' end of the segmentation arm comprises mouse gene segments CÀ2 to JÀ4 to CÀ4 and mouse À enhancer 2.4.
    [00095] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' with respect to the direction of transcription, a targeting arm to the mouse target site À5' relative to VÀ2, a cassette 5' and 3' flanked selection screen with recombinase recognition sites, a fragment of the human genome comprising a contiguous region of human À, hVÀ3 light chain site 12 downstream to the end of hJÀ, 1, and 3 ' of the target arm to target an À3 mouse sequence' relative to the JÀ2 mouse. In one embodiment, the selection cassette is a Frt’ ed neomycin cassette. In one embodiment, the 3' end of the segmentation arm comprises the mouse gene segments CÀ2 to JÀ 4 to CÀ 4 and mouse À 2.4 enhancer.
    [00096] In one aspect, an isolated DNA construct is provided, which comprises a region of the human light chain site contiguous to the À of hVÀ.3 at 12 downstream to the end of hJÀ1.
    [00097] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' with respect to the transcription direction, a targeting arm to the mouse target site 5' with respect to V À 2 , a 5' and 3' flanked selection cassette with recombinase recognition sites and a human gene fragment comprising a contiguous human light chain site region from hVÀ 3 to 27 downstream to the end of hVÀ 2 to 8 In one embodiment, the selection cassette is a Frt'ed hygromycin cassette. In one embodiment, the human gene fragment comprises a 3' target arm. In a specific embodiment, the 3' end of the targeting arm is made up of about 53 kb from the human light chain site from À hV 3 to 12 downstream to the end of hV 2 to 8.
    [00098] In one aspect, an isolated DNA construct is provided, which comprises a contiguous human light chain site region from À hVÀ.3 to 27 downstream to the end of hVÀ3 to 12.
    [00099] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' with respect to the direction of transcription, a targeting arm to the mouse target site 5' with respect to V À 2 , a 5' and 3' flanked selection cassette with recombinase recognition sites, a gene fragment comprising a first site of the human region of human A contiguous light chain À from hVÀ 5 to 52 downstream to the end of hVÀ1 to 40 , a restriction enzyme site, and a second human gene fragment, comprising a site from the human light chain region contiguous to the À of hV 3 to 29 downstream to the end of hV 82K. In one embodiment, the selection cassette is a Frt’ ed neomycin cassette. In one embodiment, the restriction enzyme site is a site for a homing endonuclease. In a specific embodiment, the homing endonuclease is PI to SCEL. Within the modality, the second fragment of the human gene is a 3' target arm. In a specific embodiment, the 3' end of the targeting arm is made up of about 27 kb from the human À light chain site of hV 3 to 29 downstream to the end of hV 82K.
    [000100] In one aspect, an isolated DNA construct is provided, which comprises a site from the human light chain region contiguous to hVÀ 5 to 52 downstream to the end of hVÀ 1 to 40.
    [000101] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' with respect to the direction of transcription, a targeting arm to the mouse's Site K of 5' with respect to the segments of Endogenous VK genes, two juxtaposed recombinase recognition sites, a 3' selection cassette for the juxtaposed recombinase recognition sites, and a 3' targeting arm to target a mouse K sequence 5' with respect to the K chain light Variable gene segments. In one embodiment, the juxtaposed recombinase recognition sites are in opposite orientation relative to each other. In a specific modality, recombinase recognition sites are different. In another specific embodiment, the recombinase recognition site is a loxP site and a lox 511 site. In one embodiment, the selection cassette is a neomycin cassette.
    [000102] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' with respect to the direction of transcription, a targeting arm to the mouse target K site 5' with respect to the segments of mouse JÀ gene, a selection cassette, a recombinase recognition site 3' of the selection cassette, and a 3' target for the target arm a mouse K sequence 3' to the JÀ and mouse gene segments 5' for a K mouse intronic enhancer. In one embodiment, the selection cassette is a TK hygromycin cassette. In one embodiment, the recombinase recognition site is in the same direction with respect to transcription as the selection cassette. In a specific embodiment, the recombinase recognition site is a loxP site.
    [000103] In one aspect, an isolated DNA construct is provided, which comprises, from 5' to 3' to the direction of transcription, a first mouse gene fragment sequence comprising 5' of the endogenous mouse VK segments of the gene, a recombinase recognition site first, a recombinase recognition site second, and a mouse second gene fragment comprising the endogenous mouse JÀ sequence 3' of gene segments and 5' of the K intronic enhancer mouse.
    [000104] In one aspect, a genetically modified mouse is provided, wherein the genetic modification comprises a modification of one or more of the DNA constructs described above or in the present invention.
    [000105] In one aspect, the use of an isolated DNA construct to make a mouse as described in the present invention is provided. In one aspect, the use of an isolated DNA construct as described herein with a method for producing an antigen-binding protein is provided.
    [000106] In one aspect, a non-human stem cell is provided that comprises a vector segmentation that comprises a DNA construct as described above and in the present invention. In one aspect, non-human stem cells is provided, wherein the non-human stem cell is derived from a mouse described in the present invention.
    [000107] In one embodiment, the non-human stem cell is one with embryonic stem cells (ES). In a specific embodiment, the ES cell is a mouse ES cell.
    [000108] In one aspect, the use of a non-human stem cell as described in the present invention to make a mouse as described in the present invention is provided. In one aspect, the use of a non-human stem cell as described in the present invention to make an antigen binding protein is provided.
    [000109] In one aspect, a mouse embryo is provided, wherein the mouse embryo comprises a genetic modification as provided in the present invention. In one embodiment, a host mouse embryo that comprises a donor ES cell is provided, wherein the donor ES cell comprises a genetic modification as described in the present invention. In one embodiment, the embryo is a pre-morula stage mouse embryo. In a specific embodiment, the pre-morula embryo stage is a 4-cell stage embryo, or an 8-cell embryo stage. In another specific modality, the mouse embryo is a blastocyst.
    [000110] In one aspect, the use of a mouse embryo as described in the present invention to make a mouse as described in the present invention is provided. In one aspect, the use of a mouse embryo as described in the present invention to make an antigen binding protein is provided.
    [000111] In one aspect, the non-human cell is provided, wherein the non-human cell comprises a genetically modified mouse-derived rearranged immunoglobulin light chain gene sequence as described in the present invention. In one embodiment, the cell is a B cell. In one embodiment, the cell is a hybridoma. In one embodiment, the cell encodes an immunoglobulin light chain Variable domain and/or an immunoglobulin heavy chain Variable domain that is somatically mutated.
    [000112] In one aspect, the non-human cell is provided, wherein the non-human cell comprises a genetically modified mouse-derived rearranged immunoglobulin light chain gene sequence as described in the present invention. In one embodiment, the cell is a B cell. In one embodiment, the cell is a hybridoma. In one embodiment, the cell encodes an immunoglobulin light chain Variable domain and/or an immunoglobulin heavy chain Variable domain that is somatically mutated.
    [000113] In one aspect, the use of a non-human cell as described in the present invention to make a mouse as described in the present invention is provided. In one aspect, the use of a non-human cell as described in the present invention to make an antigen binding protein is provided.
    [000114] In one aspect, a mouse B cell is predicted to express a light chain immunoglobulin that comprises (a) a Variable region derived from an hVÀ gene segment. and an h À gene segment, and, (b) a mouse CL gene. In one embodiment, the Mouse CL gene is selected from a CK gene and a CÀ. In a specific embodiment, the CÀ gene is CÀ2. In a specific embodiment, the Mouse Ck gene is derived from a Ck gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to from the CÀ2 mouse. In one embodiment, the mouse B cell further expresses a heavy chain comprising (c) a Variable region derived from an hVÀ, an HDH, and (d) an hJÀ segment. In one embodiment, the B cell does not include a rearranged À gene. In another embodiment, the B cell does not include a rearranged K gene.
    [000115] In one aspect, a method for producing an antibody from a genetically modified mouse is provided, which comprises: (a) exposing a genetically modified mouse to an antigen, wherein the mouse has a genome comprising at least an hVÀ and at least one hJÀ to an endogenous light chain site, where the light chain site comprises an endogenous Mouse CL gene, (b) allow the genetically modified mouse to develop an immune response against the antigen, and (c) ) isolating the mouse of (b) an antibody that specifically recognizes the antigen, or isolating from the mouse of (b) a cell that comprises an immunoglobulin domain that specifically recognizes the antigen, wherein the antibody comprises a derived light chain from an hVÀ, an hJÀ and a Mouse CL gene. In a specific modality, the CL gene mouse is a CK gene mouse.
    [000116] In one embodiment, a method for producing an antibody from a genetically modified mouse organism is provided, which comprises: (a) exposing a genetically modified mouse to an antigen, wherein the mouse has a genome comprising at least one hVÀ at an endogenous K site and at least one JÀ at the K site, where the K site comprises a mouse Ck gene, (b) allowing the genetically modified mouse to develop an immune response to the antigen; and, (c) isolating the mouse from (b) an antibody that specifically recognizes the antigen, or isolating from the mouse from (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, wherein the antibody comprises a light chain derived from an hVÀ, an hJÀ and a mouse of the CK gene.
    [000117] In one embodiment, the light chain constant K gene is selected from a human CK gene and a mouse CK gene.
    [000118] In one embodiment, a method for producing an antibody from a genetically modified mouse organism is provided, which comprises: (a) exposing a genetically modified mouse to an antigen, wherein the mouse has a genome comprising at least one hVÀ at the À light chain site and at least one JÀ at the À light chain site, wherein the À light chain locus comprises a mouse CÀ gene, (b) allowing the genetically modified mouse to develop a response immune to the antigen, and (c) isolating the mouse from (b) an antibody that specifically recognizes the antigen, or isolating from the mouse (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, or identification (b) of a nucleic acid sequence encoding an antigen-binding heavy and/or light chain Variable domain, wherein the antibody comprises a light chain derived from an hVÀ, an hJÀ and a CÀ mouse gene
    [000119] In one embodiment, the constant light chain À gene is selected from a human CÀ gene and a mouse CÀ gene. In one embodiment, the À light chain gene is a constant human CÀ gene. In a specific modality, the human CÀ gene is selected from CÀ1, CÀ2, CÀ3 and CÀ7. In one embodiment, the constant light chain À gene is a mouse CÀ gene. In a specific embodiment, the mouse CÀ gene is selected from CÀ1, CÀ2 and CÀ3. In a more specific embodiment, the mouse CÀ gene is CÀ2. In another specific embodiment, the mouse CÀ gene is derived from a CÀ gene, which is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98 % identical to CÀ2 mouse.
    [000120] In one aspect, a method for producing a rearranged antibody gene in a genetically modified mouse is provided, which comprises: (a) exposing a genetically modified mouse to an antigen, wherein the genetic modification includes an hVÀ and one hJÀ minus one endogenous light chain site, wherein the endogenous light chain site comprises a CL Mouse gene or functional fragment thereof, and (b) the identification of a rearranged immunoglobulin gene in said mouse, in which the The rearranged immunoglobulin gene comprises an À light chain of the Variable region gene segment and a CL gene or functional fragment thereof.
    [000121] In one embodiment, the method further comprises a cloning nucleic acid sequence encoding a mouse heavy and/or light chain Variable region, wherein the heavy and/or light chain Variable region is an antibody that comprises human VÀ and a mouse CL.
    [000122] In one embodiment, the Mouse CL gene or its functional fragment is selected from a human CL gene and a mouse CL gene or its functional fragment.
    [000123] In one embodiment, a method for producing a rearranged antibody gene in a genetically modified mouse is provided, which comprises: (a) exposing a genetically modified mouse to an antigen, wherein the genetic modification includes an hVÀ and an hJÀ in a light chain K Site, wherein the light chain K Site comprises a Ck Mouse gene or functional fragment thereof, and (b) the identification of a rearranged immunoglobulin gene in said mouse, in which the The rearranged immunoglobulin gene comprises an À light chain of the Variable region gene segment and a CK gene or functional fragment thereof.
    [000124] In one embodiment, the light chain constant K gene or functional fragment thereof is selected from a human CK gene and a mouse CK gene, or a functional fragment thereof.
    [000125] In one embodiment, the method further comprises a cloning nucleic acid sequence encoding a mouse heavy and/or light chain Variable region, wherein the heavy and/or light chain Variable region is a from an antibody comprising human VÀ, and a mouse CÀ.
    [000126] In one embodiment, a method for producing a rearranged antibody gene in a genetically modified mouse is provided, which comprises: (a) exposing a genetically modified mouse to an antigen, wherein the genetic modification includes a hVÀ and NÀ, in a mouse light chain À site, where the light chain À site comprises a mouse CÀ gene, or functional fragment thereof, and (b) the identification of a rearranged immunoglobulin gene in said mouse, wherein the rearranged immunoglobulin gene comprises a Variable light chain À of the gene segment and a region of the CÀ gene, or functional fragment thereof.
    [000127] In one embodiment, the fragment A of the constant light chain gene or functional thereof is selected from a human CÀ and a mouse CÀ gene or a functional fragment thereof. In a specific embodiment, the constant light chain À gene is a mouse CÀ gene or a functional fragment thereof.
    [000128] In one embodiment, the method further comprises a cloning nucleic acid sequence encoding a mouse heavy and/or light chain Variable region, wherein the heavy and/or light chain Variable region is a antibody comprising human VÀ and a mouse CÀ.
    [000129] In one aspect, a method for making an antibody is provided, which comprises exposing a mouse as described in the present invention to an antigen, allowing the mouse to mount an immune response which comprises making an antibody that specifically binds to the antigen, the identification of a rearranged nucleic acid sequence in the mouse that encodes the heavy chain and a rearranged nucleic acid sequence in the mouse that encodes a cognate light chain Variable domain sequence of an antibody, in which the antibody specifically binds to the antigen, and employs the nucleic acid sequences of the variable heavy and light chain domains fused to human constant domains to make a desired antibody, wherein the desired antibody comprises a light chain comprising an hVÀ domain, fused to a CL domain. In one embodiment, the V À domain is human and the CL domain is human or mouse domain CÀ. In one embodiment, the VÀ domain is mouse and the CL domain is human or mouse CK domain.
    [000130] In one embodiment, a method of making an antibody is provided, which comprises exposing a mouse as described in the present invention to an antigen, allowing the mouse to mount an immune response which comprises making an antibody that specifically binds to the antigen, the identification of a rearranged mouse nucleic acid sequence that encodes a heavy chain and a rearranged mouse nucleic acid sequence that encodes a cognate light chain variable domain sequence of an antibody, wherein the antibody specifically binds to the antigen, and employing heavy and light chain nucleic acid sequences fused to human constant domain nucleic acid sequences to make a desired antibody, wherein the desired antibody comprises a light chain comprising an hVÀ domain fused to a CK domain.
    [000131] In one embodiment, a method of making an antibody is provided, which comprises exposing a mouse as described in the present invention to an antigen, allowing the mouse to mount an immune response which comprises making an antibody that specifically binds to the antigen, the identification of a rearranged nucleic acid sequence in the mouse that encodes a heavy chain variable domain and a rearranged nucleic acid sequence that encodes a cognate light chain variable domain sequence of an antibody to which the antibody binds specifically to the antigen, and employing the nucleic acid sequences fused to nucleic acid sequences encoding a human heavy chain constant domain and a human constant light chain domain to make an antibody derived from human sequences, wherein the antibody is specifically binds to the antigen comprises a light chain comprising human hVA, fused to a CÀ mouse region domain.
    [000132] In one modality, the mouse region CÀ is selected from among CM, CÀ2 and CÀ 3. In a specific modality, mouse region CÀ2.
    [000133] In one aspect, a method for making an antibody rearranged light chain Variable region gene sequence is provided, which comprises (a) exposing a mouse as described in the present invention to an antigen, (b) allowing the mouse to mount an immune response, (c) identifying a cell in the mouse that comprises a nucleic acid sequence encoding the human rearranged hVÀ sequence of domain fused to a mouse CL domain, in which the cell also encodes a cognate heavy chain comprising a human VÀ domain and a mouse CH domain, and wherein the cell expresses an antibody that binds to antigen (d) from the cell cloning of a nucleic acid sequence encoding the human hVÀ domain, and a nucleic acid sequence coding for the cognate human VÀ domain, and, (e) using the cloned nucleic acid sequence coding for the human hVÀ domain, and the sequence of cloned nucleic acid encoding the human cognate V À domain to make a fully human antibody.
    [000134] In one embodiment, a method of making a rearranged antibody light chain Variable region gene sequence is provided, which comprises (a) exposing a mouse as described herein to an antigen, (b) allowing the mouse to mount an immune response, (c) identifying a mouse cell that comprises a nucleic acid sequence encoding a rearranged human hVÀ sequence from the contiguous domain on the nucleic acid molecule even with a nucleic acid sequence that encodes a mouse CK domain, wherein the cell also encodes a cognate heavy chain comprising a human VÀ domain and a mouse CH domain, and wherein the cell expresses an antibody that binds to antigen, (d) from cloning of cells of a nucleic acid sequence encoding the human VÀ domain and a nucleic acid sequence encoding the cognate human VÀ domain, and, (e) using the sequence. ia cloned nucleic acid encoding the human VA domain, and the cloned nucleic acid sequence encoding the human VA cognate domain to make a fully human antibody.
    [000135] In one embodiment, a method for making an antibody rearranged light chain Variable region gene sequence is provided, which comprises (a) exposing a mouse as described in the present invention to an antigen, (b) allowing the mouse to mount an immune response to the antigen, (c) identifying a mouse cell that comprises DNA encoding a sequence of the rearranged human domain Vk-Ck fused to a mouse domain, in which the cell also encodes a cognate heavy chain comprising a human V Á domain and a mouse of the C domain, and wherein the cell expresses an antibody that binds to antigen (d) by cloning the cell of a nucleic acid sequence encoding the domain rearranged human Vk and a nucleic acid sequence coding for the cognate human VÁ domain, and, (e) using the cloned nucleic acid sequence coding for the human hVA domain, and the sequence of Cloned nucleic acid encoding domain V is human cognate making a fully human antibody. In one embodiment, the C mouse domain is mouse CK2. In a specific modality, the mouse Ck domain is derived from a CA gene, which is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to that of the CK2 mouse.
    [000136] In one aspect, a mouse genetically modified since it expresses a human light chain, derivative fused with an endogenous light chain constant region (CO), in which the mouse, after immunization with the antigen, makes an antibody that comprises a Human Vk domain fused with a Mouse CL domain. In one embodiment, the Mouse CL domain is selected from a CK domain and a CÀ domain. In one embodiment, the Mouse CL domain is a CK domain. In one embodiment, the mouse CL domain is a certification domain. In a specific modality, the domain Ck is CK2. In a specific embodiment, the CÀ mouse domain is derived from a CÀ gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to the CK2 mouse.
    [000137] In one aspect, a genetically modified mouse comprising a modified endogenous K site or light chain K site as described in the present invention is provided that expresses a plurality of light chain immunoglobulins k associated with a plurality of immunoglobulin heavy chains . In one embodiment, the heavy chain comprises a human sequence. In various embodiments, the human sequence is selected from a Variable sequence, a hinge CH1 to CH2 to CH3, and a combination thereof. In one embodiment, the plurality of immunoglobulin À light chains comprise a human À sequence. In various embodiments, the human sequence is selected from a Variable sequence, a constant sequence, and a combination of these. In one embodiment, the mouse comprises a defective endogenous immunoglobulin locus and expresses the heavy and/or light chain of a transgene or extrachromosomal episome. In one embodiment, the mouse comprises a replacement of an endogenous mouse locus of some or all of the endogenous mouse heavy chain gene segments (ie, V, D, J), and/or some or all of the constant sequences from the endogenous mouse heavy chain (eg, hinge CH1, CH2, CH3, or one of these), and/or some or all of the sequences from the endogenous mouse from the light chain (eg, V, J, constant, or a combination ), with one or more human immunoglobulin sequences.
    [000138] In one aspect, a mouse suitable for the preparation of antibodies having a human À-derived light chain is provided, wherein all or substantially all of the antibodies produced in mice are expressed with a human À-derived light chain. In one embodiment, a human À-derived light chain is expressed from an endogenous site on the light chain. In one embodiment, the endogenous light chain site is a light chain K site. In a specific embodiment, the light chain K site is a mouse light chain K site.
    [000139] In one aspect, a method for making a human À-derived light chain for a human antibody is provided, comprising obtaining from a mouse as described in the present invention a light chain sequence and a heavy chain sequence, and employing the light chain and heavy chain sequence when making a human antibody.
    [000140] In one aspect, a method for producing an antigen-binding protein is provided, which comprises exposing a mouse as described in the present invention to an antigen, allowing the mouse to mount an immune response, and obtaining from the mouse an antigen-binding protein that binds to the antigen, or obtaining a sequence with the mouse to be used in making an antigen-binding protein that binds to the antigen.
    [000141] In one aspect, a cell derived from a mouse as described in the present invention is provided. In one embodiment, the cell is selected from an embryonic stem cell, a pluripotent cell, an induced pluripotent cell, a B cell, and a hybridoma.
    [000142] In one aspect, there is provided a cell comprising a genetic modification as described in the present invention. In one embodiment, the cell is a mouse cell. In one embodiment, the cell is selected from a hybridoma and a quadroma. In one embodiment, the cell expresses an immunoglobulin light chain that comprises a human Variable A sequence fused to a constant mouse sequence. In a specific embodiment, the constant mouse sequence is a constant mouse K sequence.
    [000143] In one aspect, a tissue derived from a mouse as described in the present invention is provided.
    [000144] In one aspect, the use of a mouse or a cell as described in the present invention to make an antigen-binding protein is provided. In one embodiment, the antigen-binding protein is a human protein. In one embodiment, the human protein is a human antibody.
    [000145] In one aspect, an antigen binding protein, made by a mouse, cell, tissue or method as described in the present invention is provided. In one embodiment, the antigen-binding protein is a human protein. In one embodiment, the human protein is a human antibody.
    [000146] The embodiments and aspects described in the present invention may be used in conjunction with one another, unless otherwise indicated or evident from the context. Other modalities will be apparent to those skilled in the art from a review of the description that follows. BRIEF DESCRIPTION OF THE FIGURES
    [000147] Figure 1 shows a detailed, non-scale illustration of the human À light chain ser locus, including the gene segment sets, hVÀ(A, B and C) and the JÀ and CÀ region pairs (J pairs to C)
    [000148] Figure 2 shows a general illustration, without scale, of an orientation strategy used to inactivate the endogenous mouse À light chain site.
    [000149] Figure 3 shows a general illustration, without scale, of an orientation strategy used to inactivate the endogenous mouse light chain K site.
    [000150] Figure 4A shows a general illustration, without scale, of an initial vector for segmentation targeting the endogenous mouse À light chain site with human À light chain sequences including 12 hVÀ gene segments and hJÀ 1 gene segment (Target vector 12/1 -À).
    [000151] Figure 4B shows a general illustration, without scale, of four initial segmentation vectors to target the endogenous mouse light chain K Site with human À light chain sequences, including the 12 hVÀ gene segments and the segment. hJÀ gene 1 (Target vector 12/1 -À), 12 hVÀ gene segments, and hJÀ 1, 2, 3 and 7 gene segments (Target vector 12/4-k), 12 hVÀ gene segments, a sequence of human Vk-Jk gene and h À 1 gene segment (Target vector 12 (K) 1-K) and 12 hVÀ gene segments, a human Vk a Jk gene sequence and hJÀ 1, 2, 3 and 7 segments of genes (Target vector 12 (K) 4-k).
    [000152] Figure 5A shows a general, non-scaled illustration of a targeting strategy for progressive insertion of 40 hVÀ gene segments and a single hJÀ gene segment into the mouse k light chain site.
    [000153] Figure 5B shows a general illustration, without scale, of an orientation strategy for progressive insertion of 40 hVÀ. gene segments and a unique hJÀ gene segment at the mouse K site.
    [000154] Figure 6 shows a general, non-scaled illustration of the orientation and molecular engineering steps employed to make the unique À -k human targeting hybrid vectors for a light chain hybrid locus construct containing a human K sequence intergenic, multiple hJÀ gene segments, or both.
    [000155] Figure 7A shows a general illustration, without scale, of the locus structure for a modified mouse À light chain locus containing 40 hVÀ gene segments. and a single hJÀ gene segment operably linked to the endogenous CÀ2 gene.
    [000156] Figure 7B shows a general non-scale illustration of the locus structure for four independent, modified mouse k light chain loci containing 40 hVÀ gene segments. and one or four hJÀ gene segments with or without a contiguous human gene VÀ to JÀ sequence operably linked to the endogenous CK gene.
    [000157] Figure 8A shows contour plots of IGÀ* and Igk* splenocytes bound to CD19+ from a wild-type (WT) mouse, a mouse homozygote for 12 hVÀ, and four segments of hJÀ genes including a human Vk to Jk gene sequence (12hV2 to V to KJÀ to 4hJÀ) and a mouse homozygote for 40 hVÀ. and an hJÀ gene segment (40hVÀ to 1hJÀ).
    [000158] Figure 8B shows the total number of CD19 + B cells in the spleen harvested from wild-type (WT) mice homozygous for 12 segments of hVÀ genes. and four hJÀ gene segments, including a human hJÀ gene sequence (12hVÀ. to Vidx to 4hJÀ) and mice homozygous for 40 hJÀ and an hJÀ gene segment (40hVÀ. to 1hJÀ).
    [000159] Figure 9A, in the upper panel, shows the closed contour plots in singlet and stained splenocytes for B and T cells (CD19 + and CD3 +, respectively) from a wild-type (WT) mouse and a homozygote of the mouse for 40 segments of hVÀ genes. and four JÀ± gene segments, including a human Vk to Jk gene sequence (40hVÀ to Vk JÀ to 4hJÀ). The bottom panel shows contour plots of splenocytes around in CD19 + and stained for expression of IG À* and Ig À* from a wild-type (WT) mouse and a mouse homozygote out of 40 hVÀ gene segments and four segments of JÀ gene including a human Vk to Jk gene sequence (40hVÀ to VKJÀ to 4hJÀ).
    [000160] Figure 9B shows the total number of CD19 +, CD19 + IGk+ and CD19+ IGÀ * cells from spleen B cells harvested from wild-type (WT) mice and homozygous mice for 40 hVÀ gene segments and four segments of JÀ gene including a human VÀ to JÀ gene sequence (40hVÀ -VkJk-4hJÀ).
    [000161] Figure 9C shows the contour of splenocyte plots around CD19 + and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from a wild-type (WT) mouse and a mouse homozygote during 40 hVÀ gene segments and four JÀ gene segments including a human Vk-Jk gene sequence (40hVÀ.-VKJk-4hJÀ). Mature (72 for WT, 51 for 40hVÀ -VkJk-4hJÀ) and transition cells (13 for WT, 22 for 40hVÀ - VkJk-4hJÀ)) B cells are noted in each of the contour plots.
    [000162] Figure 9D shows the total number of CD19 + B cells, transition B cells (CD19 + IgmhiIgDlo) and mature B cells (CD19+ IgmloIgDhi) in spleens harvested from wild-type (WT) and homozygous mice for 40 hVÀ, and four JÀ gene segments, including a human Vk-Jk gene sequence (40hVÀ. -VkJk-4hJÀ).
    [000163] Figure 10A, in the upper panel, shows the contour plots of bone marrow stain for B and T cells (CD19 + and CD3 +, respectively) of a wild-type (WT) mouse and a homozygous mouse during 40 segments of hVA genes. and four JÀ gene segments, including a human Vk to Jk gene sequence (40hVÀ a V À J a k to 4hJÀ). The bottom panel shows contour plots of surrounding CD19+ bone marrow stained for ckit+ and CD43+ from a wild-type (WT) mouse and a mouse homozygous for 40 hVÀ gene segments and four JÀ gene segments including a sequence of human gene VÀ to JÀ (40hVÀ. to VKJÀ to 4hJÀ). Pre- and Pro-B cells are annotated in the contour plots of the background panel.
    [000164] Figure 10B shows the number of Pro (CD19 + CD43 + ckit +) and Pre (CD19 + CD43 ckit +) B B cells in bone marrow harvested from femurs of wild-type (VVT) and homozygous mice for 40 hVÀ gene segments and four J2 gene segments, including a human Vk-Jk gene sequence (40 hVÀ.VkJk-4hJÀ).
    [000165] Figure 10C shows bone marrow contour plots around singlets stained for immunoglobulin M (IgM) and B220 from a wild-type (WT) mouse and a mouse over 40 segments of homozygous hVÀ genes. and four JÀ± gene segments including a human Vk to Jk gene sequence (40hVÀ± to Vidx to 4hJÀ). Immature, mature, and pro/pre B cells are noted on each of the contour plots.
    [000166] Figure 10D shows the total number of immature (B220IntIgM+) and mature (B220hiIgM+) B cells in bone marrow isolated from femurs of wild-type (WT) and mice homozygous for 40 hVÀ gene segments and four segments of JÀ genes including a human VÀ to JÀ gene sequence (40hVÀ - VkJk-4hJÀ).
    [000167] Figure 10E shows bone marrow contour plots around immature (B220hiIgM+) and mature (B220hilgM+) B cells stained for expression of Ig À and Igk isolated from femurs of a wild-type (WT) mouse and a mouse homozygote for 40 hVÀ gene segments and four JÀ gene segments including the human Vk-Jk gene sequence (40hVÀ.-VkJk-4hJÀ.).
    [000168] Figure 11 shows an alignment of nucleotide sequences of the VÀ -JÀ -Ck junction of 18 independent of the RT to PCR clones amplified from RNA clones of splenocytes of light chain gene sequences from human carrier mice À a an endogenous mouse light chain K site. A6 = SEQ ID NO: 57; B6 = SEQ ID NO: 58; F6 = SEQ ID NO:59; B7 = SEQ ID NO: 60; E7 = SEQ ID NO: 61; F7 = SEQ ID NO: 62; C8 = SEQ ID NO: 63; E12 = SEQ ID NO: 64; 1 to 4 = SEQ ID NO: 65; 1 to 20 = SEQ ID NO: 66; 3B43 = SEQ ID NO: 67; 5 to 8 = SEQ ID NO: 68; 5 to 19 = SEQ ID NO: 69; 1010 = SEQ ID NO: 70; 11A1 = SEQ ID NO: 71; 7A8 = SEQ ID NO: 72; 3A3 = SEQ ID NO: 73; 2 to 7 = SEQ ID NO: 74. Lowercase bases indicate non-germline bases resulting from either mutation and/or addition N during recombination. The consensus amino acids within framework region 4 (FWR4) encoded via the nucleotide sequence of hJÀ 1 and mouse CK are seen in the background of the sequence alignment.
    [000169] Figure 12 shows an alignment of the nucleotide sequence of the V A -JÀ -Ck junction of 12 independent of RT to PCR amplified from human mouse splenocyte RNA clones carrying light A chain gene sequences, including a contiguous Vk to Jk human gene sequence in an endogenous mouse light chain K Site. 5 to 2 = SEQ ID NO: 87; 2 to 5 = SEQ ID NO: 88; 1 to 3 = SEQ ID NO: 89; 4B to 1 = SEQ ID NO: 90; 3B to 5 = SEQ ID NO: 91; 7A to 1 = SEQ ID NO: 92; 5 1 = SEQ ID NO: 93; 4A to 1 = SEQ ID NO: 94; 11A to 1 = SEQ ID NO: 95; 5 to 7 = SEQ ID NO: 96; 5 to 4 = SEQ ID NO: 97; 2 to 3 = SEQ ID NO: 98. Lowercase bases indicate non-germline bases resulting from either mutation and/or addition N during recombination. The consensus amino acids within framework region 4 (FWR4) encoded by the nucleotide sequence of each human JÀ and mouse CK are seen in the background of the sequence alignment.
    [000170] Figure 13 shows a nucleotide sequence alignment of the VÀ -JÀ -CÀ junction of three independent RT to PCR clones amplified from mouse splenocyte RNA clones carrying the light chain gene sequence sites human, and from the sequences of the endogenous mouse À light chain gene. 2D1 = SEQ ID NO: 101; 2D9 = SEQ ID NO: 102; 3E15 = SEQ ID NO: 103. Lowercase bases indicate non-germline bases resulting from either mutation and/or the addition of N during recombination. The consensus amino acids within framework region 4 (FWR4) encoded by the mouse hJÀ 1 and CÀ2 nucleotide sequence are indicated at the bottom of the sequence alignment. DETAILED DESCRIPTION
    [000171] Although the specific features of the various embodiments are discussed in detail, the descriptions of the specific aspects, the embodiments and the examples do not limit the scope of the claims, it is the claims that describe the scope of the present invention. All terms and expressions used in this specification include the meanings ascribed to them commonly in the art.
    The term "contiguous" includes reference to occurrence in the same nucleic acid molecule, for example, two nucleic acid sequences are "contiguous" if they occur in the same nucleic acid molecule but are interrupted by another nucleic acid sequence. For example, a rearranged V(D)J sequence is "contiguous" to a gene constant region sequence, even though the final codon of the V(D)J sequence is not immediately followed by the first codon of the constant region sequence. In another example, the two V gene segment sequences are "contiguous" if they occur in the same gene fragment, although they can be separated by means of a sequence that does not encode a V region codon, for example, they can be separated by a regulatory sequence, for example a promoter or a non-coding sequence of another. In one embodiment, a contiguous sequence includes a gene fragment containing the arranged gene sequences as found in a wild-type genome.
    [000173] The phrase "derived from", when used over a Variable region "derived from" a quoted gene or gene segment includes the ability to detect the sequence back to a particular unrearranged gene segment or gene segments. genes that have been rearranged to form a gene that expresses the Variable domain (which corresponds, where appropriate, to slicing differences and somatic mutations).
    [000174] The phrase "functional" when used over a Variable region gene segment or appended to a gene segment refers to the use of a repertoire of expressed antibodies; for example, in human VÀ gene segments 3 to 1.4 to 3, 2 to 8, etc. are functional, whereas VÀ gene segments 3 to 2, 2 to 5, 3 to 4, etc. are non-functional
    [000175] The "heavy chain site" includes a location on a chromosome, eg a mouse chromosome, where in a mouse wild-type heavy chain variable (V To ), the heavy chain diversity ( DH), the heavy chain junction (JÀÀ), and heavy chain constants (CH) of the DNA region sequences are found.
    [000176] The "K site" includes a location on a chromosome, eg a mouse chromosome, where in a wild-type mouse variable k (V À), junction of K (Jk), and constant K ( Ck) of the DNA region sequences are found.
    [000177] The "À site" includes a location on a chromosome, eg a mouse chromosome, where in a mouse wild-type variable À (VÀ), the junction of À (JÀÀ), and the constant À (CÀ.) of the DNA region sequences are found.
    [000178] The term "unrearranged" includes the locus state of an immunoglobulin in which the V gene segments and J gene segments (for the heavy chains, the D gene segments as well) are kept separate, but are capable of being spliced together in order to form a rearranged V(D) J gene comprising a single V, (D), J of the V (D) J repertoire. Mice Expressing Human Variable Domains
    [000179] Mice expressing antibodies that are either fully human, or partially human and partially mouse, have previously been reported. The genetically modified VELOCALMMUNE ® mice comprise a replacement of unrearranged V(D)J gene segments in place of the endogenous mouse gene segments with human V(D)J. VELOCALMMUNE ® mice express chimeric antibodies having human Variable domains and mouse constant domains (see, for example, U.S. Patent No. 7,605,237). Most reports speak of other mice expressing concern for fully human antibodies to fully human transgenes in mice that have disabled the endogenous immunoglobulin locus.
    [000180] Antibody light chains are encoded by one of two distinct loci: kappa (k) and lambda (À). Mouse antibody light chains are mainly of the K type. Mice that produce mouse antibodies and modified mice that make the mouse fully human or human chimeric exhibit a bias in the use of the light chain. Humans also have a light chain bias, but it is not as pronounced as in mice, the ratio of K light chains to À light chains in mice is about 95:5, whereas in humans the ratio is about 95:5. around 60:40. The most pronounced orientation in mice is not thought to severely affect antibody diversity, because in the mouse the À Variable site is not as diverse in the first instance. This is not so in human beings. The human À light chain site is rich in diversity.
    [000181] The human À light chain site spans 1000 kb and contains more than 80 genes that encode the Variables (V), or the joints (J) (Figure 1). Within the human À light chain site more than half of all observed domains are encoded via gene segments 1 to 40, 1 to 44, 2 to 8, 2 to 14, and 3 to 21. Overall, about 30 or more of the human VÀ gene segments are believed to be functional. There are seven JÀ gene segments, only four of which are considered to be generally functional JÀ gene segments at JÀ 1, JÀ 2, JÀ 3, and JÀ 7.
    [000182] The human light chain site is similar in structure to the K site in both mice and humans, in that the human À light chain site has several Variable region gene segments, which are able to recombine to form a functional light chain protein. The human À light chain site contains approximately 70 V gene segments and 7 JA to Ck pair gene segments. Only four of these pairs of JÀ to Ck gene segments appear to be functional. In some alleles, a fifth pair of gene segment J1 to CA is reportedly a pseudo gene (CÀ 6). 70 hVÀ gene segments appear to contain 38 functional gene segments. The 70 Vk sequences are arranged in three groups, which contain the different distinct members of the V family gene groups (groups A, B and C FIG 1). This is a rich source of relatively untapped diversity potential for the generation of antibodies with human V regions in non-human animals.
    [000183] In contrast, the human À light chain site contains only two or three (Depending on the strain) of mouse gene segments from the Vk region (Figure 2). For this reason at least, severe K bias in mice is not thought to be particularly detrimental to total antibody diversity.
    [000184] According to published mouse À light chain site maps, the site consists essentially of two sets of gene segments within a range of about 200 kb (Figure 2). The two groups contain two sets of genes V, J and C that are capable of independent rearrangement: VK2 to JÀ 2 to CK2 to JÀ 4 to CK4 and V À 1 to JÀ 3 to CÀ 3 to JÀ 1 to CK1. Although V À 2 has been found to recombine with all gene segments, JÀ, V À 1 appears to exclusively recombine with CK1. CK4 is believed to be a defective pseudogene with splice sites.
    [000185] The light chain K Site mouse is very different. The structure and number of gene segments that participate in the recombination events that lead to a functional local mouse K light chain protein is much more complex (Figure 3). In this way, mouse and light chains do not contribute much to the diversity of an antibody population in a normal mouse.
    [000186] Exploiting the rich diversity of the human À light chain site in mice would likely result in, among other things, a source of a more complete human repertoire of light chain V domains. Previous attempts to exploit this diversity have used human transgenes that contain pieces of the human À light chain site randomly incorporated into the mouse genome (see, for example, US 6998514 and US 7,435,871). Mice that contain these randomly integrated transgenes supposedly express fully human À light chains, however, in some cases, one or both of the endogenous light chain site remain intact. This situation is not desirable, as the human À light chain sequences compete with the mouse light chain (lc or À) in the mouse expressed antibody repertoire.
    [000187] In contrast, the inventors describe genetically modified mice that are capable of expressing one or more À light chain nucleic acid sequences directly from a mouse light chain site, including replacement of a mouse locus of endogenous light chain. Genetically engineered mice capable of expressing human light chain À sequences from an endogenous locus can be further bred to mice comprising a human heavy chain locus and thus be used to express antibodies comprising V regions (heavy and light), who are fully human. In various modalities, V regions are expressed with constant mouse regions. In various embodiments, non-endogenous mouse immunoglobulin gene segments are present and the V regions express with the human constant regions. These antibodies would be useful in numerous applications, both diagnostic and therapeutic.
    [000188] Many advantages can be realized through various modalities of expression of human VÀ-derived binding proteins and JÀ gene segments in mice. Advantages can be realized by placing human À sequences at an endogenous light chain site, for example, the mouse K or À locus. Antibodies produced from such mice can have light chains that comprise the human VÀ domains fused to a Mouse CL region, specifically a mouse CK or CÀ region. Mice also express human VÀ domains that are suitable for identification and cloning for use with human CL regions, specifically the CK and/or CÀ regions. Because B cell development in mice such is otherwise normal, it is possible to generate compatible VÀ domains (including somatically mutated VÀ domains) in the context of one of the CÀ À, or CK regions.
    [000189] Genetically modified mice are described which comprise an unrearranged immunoglobulin VÀ gene segment or an À light chain K Site. Mice expressing antibodies comprising a light chain having a human VÀ domain fused to a CK region and/or CÀ are described. Sterile Immunoglobulin Light Chain K Site Transcripts
    [000190] Variations on the subject of expression of human immunoglobulin sequences in À mice reflect various modalities of genetically modified mice capable of such expression. Thus, in some modalities, genetically modified mice comprise non-coding sequence(s) determined from a human locus. In one embodiment, the genetically engineered mouse comprises human VÀ. JÀ and endogenous gene segments, to a K light chain site, and further comprises a human K light À chain gene fragment. In a specific embodiment, the human K light chain gene fragment is a non-coding sequence found naturally between a human VK gene segment and a human JÀ gene segment.
    [000191] The mouse and human light chain K site contains sequences that encode sterile transcripts that do not have either start codon or an open reading frame, and that are considered to regulate transcription of the site. of the light K chain. These sterile transcripts arise from an intergenic downstream sequence located either 3' of the most proximal segment and Vk gene upstream or 5' of the light chain K intronic enhancer (EKI) which lies upstream of the light chain K gene constant region (CK). Sterile transcripts arise from rearrangement of the intergenic sequence to form a segment of VKJÀ 1 fused to a CK.
    [000192] Replacement of the K light chain site upstream of the CK gene would remove the intergenic region encoding the sterile transcripts. Therefore, in various embodiments, a light chain K mouse sequence replacement upstream of the mouse gene with human CK À light chain gene segments would result in a humanized mouse Light chain K site that contains human Vk and segments of JÀ genes, but not the intergenic K light chain region that encodes the sterile transcripts.
    [000193] As described herein, humanization of the endogenous mouse A light chain K-site with humans, the light chain gene segments, in which humanization removes the intergenic region, results in a notable decrease in site utilization. K light chain, along with a marked increase in the use of the light chain. Therefore, although a humanized mouse that lacks the intergenic region is useful in that they can produce human antibodies with Variable light chain domains (eg, , human, or K domains), site utilization decreases.
    [000194] Humanization of the endogenous mouse K site of the light chain with human V À is also described. À and JÀ gene segments, together with an insertion of a human K intergenic region to create a Vk site that contains, with respect to transcription, between the final human Vk gene segment and the first human JÀ gene segment, the the intergenic region, K which exhibits a population of B cells with increased expression from a locus lacking the intergenic K region. This observation is consistent with the hypothesis that the intergenic region is directly through sterile transcription, or indirectly from the use suppresses endogenous À. light chain site. Under such a hypothesis, including the intergenic region would result in a decreased utilization of the endogenous light k chain site, leaving the mouse a restricted choice but to employ the modified (in À) site to generate antibodies.
    [000195] In various modalities, the replacement of mouse sequence of the K light chain upstream of the human Mouse Ck gene with light chain À sequence further comprises a human K light chain intergenic region disposed, in relation to transcription, between the region 3' untranslated from the 3' end of the Vk gene segment and further 5' from the first human JA gene segment. Alternatively, such an intergenic region can be omitted from an endogenous substituted K light chain site (upstream of the Mouse Ck gene) by making a deletion at the endogenous 2 light chain site. Likewise, within the scope of the present exemplary embodiment, the mouse generates antibodies from an endogenous K light chain site containing human A light chain sequences. Approaches to Engineering Mice that Express Human hVÀ Domains.
    [000196] Several approaches to make genetically modified mice that produce antibodies that contain a light chain that has a human VÀ domain fused to an endogenous Cr region (eg, CK or CÀ À ,) are described. Genetic modifications are described which, in various embodiments, comprise a deletion of one or both of the endogenous light chain site. For example, to eliminate the mouse À Light chains from the repertoire of endogenous antibodies a deletion of a first Vk a JÀ to CÀ À , clustering of replacement genes and, in whole or in part, of the gene segments JÀ VÀ a of a Second human gene cluster with Vk to JÀ gene segments can be made. Genetically modified mouse embryos, cells and segmentation constructs to make mice, mouse embryos and cells are also provided.
    [000197] The elimination of an endogenous VÀ to JÀ to CA, gene cluster replacement of the gene segments of a VÀ -JÀ -CÀ gene cluster employs relatively minimal disruption in the single antibody constant region association and function in the animal, in various modalities, because the endogenous CA genes are left intact and therefore maintain normal functionality and ability to associate with the constant region of an endogenous heavy chain. Thus, in such embodiments the modification does not affect other endogenous heavy chain constant regions dependent on functional light chain constant regions for the assembly of a functional antibody molecule that contains two heavy chains and two light chains. Furthermore, in several modalities the modification does not affect the assembly of a functional membrane-bound antibody molecule involving an endogenous heavy chain and a light chain, eg, an hVÀ, domain linked to a mouse region CÀ At least one gene Functional CÀ is retained in the endogenous locus, animals that contain a substitution of VÀ to JÀ gene segments of an endogenous gene cluster Vk to JÀ - CÀ, with human VÀ to JÀ gene segments should be able to make normal light chains A that are capable of binding to antigen, during an immune response through human VÀ to JÀ gene segments present in the animal's expressed antibody repertoire.
    [000198] A schematic illustration (not to scale) of an endogenous VÀ to JÀ excluded mouse. the Ck gene cluster is provided in Figure 2. As illustrated, the mouse À light chain site is organized into two gene clusters, which contain gene function segments capable of recombining to form a mouse light chain function À . The endogenous mouse Vk1 to JÀ 3 to CK3 to JÀ 1 to CA, group 1 gene is eliminated by a segmentation construct (Segmentation Vector 1) with a neomycin cassette flanked by a recombination site. The other endogenous gene cluster (VK2 to VK3 to JÀ 2 to CK2 to JÀ 4 to CK4) is eliminated in part by a targeting construct (Vector Segmentation 2) with a hygromycin thymidine kinase cassette flanked by recombination sites. In this second segmentation event, the endogenous CÀ2 to JÀ 4 to CÀ 4 gene segments are retained. A second segmentation construct (Target Vector 2) is constructed using recombination sites that are different than those in the first segmentation construct (Target Vector 1) thus allowing selective elimination of the selection cassette after a segmentation has been successful. The resulting double-segmented locus is functionally silenced in that no endogenous light chain can be produced. This modified site can be used for insertion of human VÀ and J1. gene segments to create an endogenous mouse A locus comprising human VÀ and JÀ gene segments, where, upon recombination at the modified site, the animal produces light chains comprising rearranged human VÀ and JÀ gene segments linked to an endogenous CA mouse , gene segment.
    [000199] The mouse genetically modified to make endogenous À gene segments non-functional, in various modalities, results in a mouse that exclusively presents the K light chains from its antibody repertoire, making the mouse useful to assess the role of light chains À in the immune response is useful for making an antibody repertoire comprising the Vk domains but not the hVÀ domains.
    [000200] A genetically modified mouse that expresses an hVÀ linked to a mouse CÀ gene having been recombined into the endogenous mouse À light chain site can be made by any method known in the art. A schematic illustration (not to scale) of endogenous mouse replacement segments VK2 to VK3 to JÀ 2 genes with human VÀ and JÀ gene segments is provided in Figure 4 À. As illustrated, an endogenous mouse at the light chain site that had been rendered non-functional is replaced by a targeting construct (12/1 to k Target vector), which includes a neomycin cassette flanked by the recombination site. The VK2 to V À 3 to JÀ gene 2 segments are replaced by a gene fragment containing human À of sequence that includes 12 hVÀ gene segments and a single hJÀ gene segment.
    [000201] Thus, this first approach of the positions of one or more hVÀ gene segments in the endogenous À, light chain site contiguous with a single hJÀ gene segment (Figure 4A).
    [000202] Further modifications to the modified endogenous À light chain site can be achieved using similar techniques to insert the more hVÀ gene segments. For example, schematic illustrations of two new targeting constructs (+16 to k and +12 to Vector targets) used for the progressive insertion of addition human hVÀ gene segments are provided in Figure 5À. As illustrated, additional containing gene fragments specific to the human hVÀ gene segments are inserted into the modified endogenous À light chain site, in successive steps using homology provided by the previous insertion of the human light chain sequences. After recombination with each illustrated targeting construct, in sequence, 28 additional hVÀ gene segments are inserted into the modified endogenous light chain site. This creates a chimeric site that produces an À, light chain protein that comprises human gene segments VÀ to JÀ linked to a mouse CÀ gene.
    [000203] The above approaches to inserting the human light chain À gene segments into the mouse keep the enhancers positioned downstream of the segments from CK2 to JÀ 4 to CK4 genes (designated Enh 2.4, Enh Enh and 3.1 figure 4A and Figure 5A). This approach results in a single modified allele at the endogenous mouse À light chain site (Figure 7A).
    [000204] Compositions and methods for making a mouse that expresses a light chain comprising hVÀ and JÀ gene segments operably linked to a mouse CÀ À gene segment are provided, including compositions and method for making a mouse that expresses from such endogenous mouse genes an , light chain site. Methods include selectively providing an endogenous mouse Vk to JÀ. the CÀ gene clustering non-functional (eg, by a target deletion), and employing an hVÀ and JÀ gene segments at the endogenous mouse À light chain site expressing an hVÀ domain in a mouse .
    [000205] Alternatively, in a second approach, the human light chain gene segments can be positioned at the endogenous K light chain site. Genetic modification, in various embodiments, comprises a deletion of the endogenous K light chain site. For example, to eliminate mouse K light chains from the endogenous antibody repertoire a deletion of mouse VK and JÀ gene segments can be made. Genetically modified mouse embryos, cells and segmentation constructs to make mice, mouse embryos and cells are also provided.
    [000206] For the reasons stated above, deletion of mouse VK and JÀ gene segments employs relatively minimal disruption. A schematic illustration (not to scale) of deleted mouse VK and JÀ gene segments is provided in Figure 3. Endogenous mouse Vk and JÀ gene segments are deleted by mouse position deletion-mediated recombinase mediated between two sequences of precisely positioned segmentation vectors each employing site-specific recombination. A first target vector (Target vector plc) is employed in a first event in order to exclude the JÀ mouse gene segments. A second targeting vector (Vk target vector) is employed in a second sequential targeting event of a sequence located 5' to the most distal gene of the mouse VK segment. Both vectors contain target sites specific to the recombination site, thus allowing selective deletion of both selection cassettes and all intervening mouse K light chain sequences after targeting one was successful. The resulting excluded site is functionally silenced in which no endogenous K light chain can be produced. This modified site can be used for insertion of hVÀ, and JÀ gene segments to create an endogenous mouse K Site comprising hVÀ. and JÀ gene segments, in which, upon recombination at the modified site, the animal produces A comprising hVÀ light chains and rearranged JÀ gene segments operably linked to an endogenous mouse CK gene segment. Various targeting vectors comprising the two light chain sequences can be used in conjunction with this mouse deleted K site to create a light chain site containing the human hybrid gene A segments operably linked to a Mouse Ck region.
    Thus, the second approximation positions of one or more human VÀ gene segments are positioned in the mouse light chain K site contiguous with a single human JÀ gene segment (12/1 to K Target vector, Figure 4B) .
    [000208] In various embodiments, modifications to this approach can be made to add gene segments and/or regulatory sequences to optimize the K site utilization of mouse human A light chain sequences within the mouse antibody repertoire .
    [000209] In a third approach, one or more hVÀ gene segments. are positioned at the mouse K light chain site contiguous with four gene sequences (hJÀ 12/4 to K Target Vector Figure 4B).
    [000210] In a third approach, one or more segments of the hVÀ gene. are positioned in the mouse K light chain site with a contiguous intergenic human K sequence and a unique hJÀ gene sequence (12001 x a Target vector, Figure 4B).
    [000211] In a fourth approach, one or more segments of the hVÀ gene. are positioned at the mouse K light chain site contiguous with a human K intergenic sequence of four hJÀ gene sequences (12004 K to Target Vector Figure 4B).
    [000212] All of the above approaches to insert human 2 light chain gene segments into mouse K Site, maintain the K intronic enhancer element upstream of the Cic gene (Designated EKI, Figure 4B and Figure 5B) and 3' downstream of K and CK gene enhancer (designated EK3', Figure 4B and Figure 5B). The result of four separate approaches to modified alleles in the endogenous mouse Site K light chain (Figure 7B).
    [000213] In various configurations, genetically modified mice comprise a knockout of the endogenous mouse À site of the light chain. In one embodiment, the À light chain site is eliminated by a strategy that excludes the region spanning the V À 2 JÀ 2, and the region spanning the vkl CKL (Figure 2). Any strategy that reduces or eliminates the ability of the endogenous À, light chain site to express the endogenous À domains is suitable for use with the embodiments of the present disclosure. Lambda Domain Antibodies from Genetically Modified Mice
    [000214] Mice comprise the human À sequences in both mouse K and the À light chain expressing a light chain site that comprises an hVÀ region. fused to a Mouse CL region (CK or CÀ ). These are advantageously produced for mice that (a) comprise a functionally silenced light chain site (eg, an endogenous K mouse knockout or À light chain site), (b) comprise an endogenous À mouse light chain site that comprises hV and hJ gene segments operably linked to an endogenous mouse CÀ À, gene, (c) comprises an endogenous mouse light chain K Site comprising hVÀ. and hJÀ gene segments operably linked to an endogenous mouse CK gene, and, (d) wherein a mouse a K allele comprises hVÀ.s and hJÀs, the K allele and another comprising hVÀs hJÀs; an hVÀ s À allele comprising and hJÀ s and an À allele silenced or deleted, or both À alleles comprising hVÀs and hJÀs, and, heavy chain of two alleles that each make up hVÀ s, hDHs and hJÀ s.
    Antibodies comprising the hVÀ domains expressed in the context of CK or CÀ are used to produce fully human antibodies by cloning the nucleic acids encoding the hVÀ domains into expression constructs that carry the genes encoding human CÀ. The resulting expression constructs are transfected into suitable host cells for the expression of antibodies that exhibit an all-hVÀ domain fused to HCÀ EXAMPLES
    [000216] The following examples are provided in order to describe how to prepare and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Unless otherwise noted, temperature is indicated in degrees Celsius, and pressure is at or near atmospheric. Example I Mouse Immunoglobulin Light Chain Site Deletion
    [000217] Several targeting constructs were made using VELOCALGENE ® technology (see, for example, US Patent No. 6,586,251 and hVÀ lenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis , Nature Biotech.21(6):652 to 659) to modify mouse bacterial chromosome Artificial gene libraries (BAC) to inactivate mouse light chain K and À site. Mouse light chain À site deletion. BAC clone RP23 mouse DNA at 135k15 (Invitrogen) was modified through homologous recombination to inactivate the endogenous mouse À, light chain site through target deletion of the Vk to JÀ, to CÀ, gene clusters (Figure 2).
    [000218] In summary, the entire proximal cluster comprising gene VM to R3 to CÀ 3 to R1 to CÀ 1 segments was suppressed in a single target event using a targeting vector comprising a site-flanked / OXP neomycin cassette with a 5 arm. 'mouse homology containing the 5' sequence of the V À .1 gene segment and a 3' of the mouse homology arm containing the 3' sequence of the CÀ gene segment (Figure 2, Target vector 1).
    [000219] A second target construct was prepared to precisely exclude the endogenous distal mouse À gene pool containing VÀ,2 to JÀ 2 to CÀ2 to JÀ 4 to CK4 except that the target construct contained a 5' mouse homology arm that contained sequence 5 ' the V À 2 gene segment and 'mouse homology arm, which contained the 5' to 3 sequence for the endogenous gene segment CÀ2 (Figure 2, Target vector 2). À 2 to JÀ 2, leaving CÀ2 to JÀ .4 to CÀ 0.4 intact in the endogenous mouse À local ES cells containing an inactihVÀ of the endogenous À local (as described above) were confirmed by screening and karyotyping methods (eg , TaqMan ®) known in the art. The DNA was then isolated from the modified ES cells and subjected to a treatment with the enzyme Cre recombinase, thereby mediating the suppression of the proximal target cassette containing the neomycin marker gene, leaving only one site / OXP at the point of exclusion (Figure 2, bottom). Exclusion of the mouse light chain k site. Several targeting constructs were made using methods similar to those described above to modify the DNA of mouse BAC clones RP23 to 302g12 and RP23 to 254m04 (Invitrogen) by homologous recombination to inactivate the mouse light chain K-site in a two-step process (Figure 3).
    [000220] Briefly, JÀ gene segments (1 to 5) of the endogenous mouse light chain K locus were eliminated in a single targeting event using a targeting vector comprising a hygromycin thymidine kinase cassette (hyg to TK) containing a single / OXP site 3' relative to cassette hyg to TK (Figure 3, JÀ Target vector). The homology arms used to make this vector segmentation contained the 5' and 3' mouse gene sequences of the endogenous JÀ mouse gene segments. In a second targeting event, a second targeting vector was prepared to delete a portion of the mouse gene sequence upstream (5') to the most distal endogenous mouse Vk gene segment (Figure 3, VK Target vector). This vector contained an inverted targeting site / ox511, a / OXP site and a neomycin À cassette. The homology arms used to make this targeting vector mouse gene sequence contained upstream of the most distal mouse gene segment Vk. Target vectors were used in a sequential fashion (i.e. then Vk JÀ) to target DNA into ES cells. ES having a dual-to-target chromosome (ie, a single endogenous K-Site target mouse, with both targeting vectors) were confirmed by screening and karyotyping methods (eg, TaqmanTm) known in the art. DNA was then isolated from the modified ES cells and subjected to a treatment with the enzyme Cre recombinase, thereby mediating the elimination of endogenous mouse VK segments from genes and both selection cassettes, while leaving two lox sites juxtaposed in opposite orientation relative to the other (figure 3, bottom, SEQ ID NO: 1).
    [000221] In this way, two modified endogenous light chain sites (lc and À) containing intact promoter and constant regions were created to progressively insert the unrearranged human 2 insertion. germline gene segments in a precise manner using target vectors described below. Example II Replacement of mouse light chain site with a Human A light chain minisite
    [000222] Several segmentation vectors have been designed for the progressive insertion of human k endogenous mouse gene segments into the K and À light chain site, using methods similar to those described above. endogenous light chains each producing a chimeric light chain site containing hVÀ. and JÀ gene segments operably linked to mouse constant light chain genes and enhancers. A mini-site À . human containing 12 human VÀ and a human J gene segment.
    [000223] A series of initial segmentation vectors were designed to contain the first 12 consecutive human Vk gene segments One cluster and one hJÀ gene segment 1 or four hJÀ gene segments using a human BAC clone called RP11 to 729g4 (Invitrogen ). FIGs. 4A and 4B show the segmentation vectors, which were constructed to make an initial insertion of human À light chain chain gene segments into the mouse and light chain site, respectively.
    [000224] During a first set of initial targeting vectors, one per 124,125 DNA fragment of the 729g4 BAC clone containing 12 hVÀ gene segments. and an hJÀ 1 gene segment was modified to contain a PI site to SCEL 996 by downstream (3') of hJ7, a gene segment for linking a 3' of the mouse homology arm. Two different sets of homology arms were used for binding to this human fragment, one set of mouse homology arms contained endogenous À sequences from BAC clone 135k15 (Figure 4A) and another set contained endogenous 5' and 3' K sequence from mouse and mouse VK JÀ gene segments from mouse BAC clones RP23 at 302g12 and RP23 at 254m04, respectively (Figure 4B).
    [000225] For the 12/1 to À , Target vector (Figure 4A), a PI to SCEL site was designed at the 5' end of a 27847 DNA fragment containing the mouse CK2 to J .4 to CK4 and 2.4 enhancer of the mouse À modified, site described in Example 1. The mouse fragment at 28 kb was used as a 3' homology arm by linking to the human 124 kb fragment, which created a 3' junction containing, from 5' to 3 ', a hJÀ .1,996 gene segment by human À sequence 3' of the h .. 1k1 gene segment, 1229 by mouse À sequence 5' of the CÀ2 mouse gene, the CK2 mouse gene and the part remainder of the mouse fragment at 28 kb. Upstream (5' ) from the human segment VK3 to 12 was an additional 1456 gene of a human sequence, before the beginning of the 5' end of the mouse homology arm, which contained 23,792 µg of mouse gene DNA corresponding to the 5' sequence of the local endogenous mouse À. Between the 5' end of the homology arm and the beginning of the human À sequence was a neomycin cassette flanked by the DRF site.
    [000226] Thus, a target Vector 12/1 to À . included, from the 5' to 3', 5' homology arm containing the 24 kb mouse X 5' gene sequence of the endogenous X site, a 5' Frt site, a neomycin cassette, a 3' site DRF, a 123 kb of human gene sequence containing the first consecutive 12 hVX, gene segments and an hJX .1 gene segment, a P1 to SCEL site, and a "homology arm containing the 28 kb of gene sequence of the mouse including the endogenous CK2 to JX segments,4 to CM gene, the mouse 2,4 enhancer sequence and additional downstream mouse gene sequence (3' 3) of the 2,4 enhancer (Figure 4A).
    [000227] In a similar fashion, the 12/1 ax Target Vector (Figure 4B) used the same 124X human fragments with the exception that the mouse homology arms containing mouse K sequence were used in such a way that the targeting to the endogenous K site can be achieved through homologous X recombination In this way, the 12/1 ax Targeting vector included, from 5' to 3', a "homology arm containing the 23 kb mouse gene sequence 5' 5 of the endogenous Site K, a I to Ceul site, a 5' Frt site, a neomycin cassette, a 'DRF site, 124 kb of human sequence X of the gene containing the first consecutive 12 hVX, gene segments and an NM gene segment, a PI site to SCEL, and a 3' 3 homology arm containing the 28 kb mouse gene sequence, including the endogenous Mouse gene Ck, Exi and Ex3' and other gene sequences of mouse downstream (3') of EK3' (Figure 4B, 12/1 a K Target vector).
    [000228] Homologous recombination with either of these two initial segmentation vectors created a local mouse light chain modification (1 (or X ) containing 12 hVX . gene segments and an hJX .1 gene segment operably linked to the endogenous mouse gene constant light chain and enhancers (CK or CÀ2 and Eki/Ek3' or 2.4 Enh / Enh 3.1) of the gene which, after recombination, leads to the formation of a chimeric À light chain. A mini-site À . human containing 12 human VÀ and four human J gene segments.
    [000229] In another approach to add diversity to a chimeric À light chain site, an initial third-shot vector was designed to introduce the first consecutive human 12 V . from gene cluster A and hJÀ segments 1, 2, 3 and 7 gene segments to mouse K light chain site (Figure 4B, 12/4 a x Target vector). A DNA segment containing hJÀ , 1, JÀ 2 , JÀ , 3 and JÀ .7 gene segments was made by new DNA synthesis (Integrated DNA Technologies), each including one JÀ . gene segment and human gene sequence from to 100 by both the immediate 5' and 3' of each segment of JÀ gene regions. A P1 to SCEL site was designed to the 3' terminus of the 1 kb DNA fragment present and ligated to a chloroamphenicol cassette. Homology arms were amplified by PCR from human À, sequence 5' and 3' to the position of the hJÀ gene segment 1 of human BAC clone 729g4. Homologous recombination with this target intermediate vector was performed in a modified BAC clone 729g4 that had been previously targeted upstream (5' ) of the human V À 3 to 12 segment with a FRT site-flanked neomycin gene cassette, which also contained a site from I to Ceul 5' from site 5' Frt. A double a target 729g4 BAC clone included from 5' to 3', an I to Cell site, a 5' Frt site, a neomycin cassette, a 3' DRF site, a 123 kb fragment containing 12 segments of hVÀ genes, a fragment containing the 1 kb human JÀ 1, 2, 3, and 7 gene segments, a PI site to SCEL, and a chloroamphenicol cassette. This intermediate vector was target digested along with I to Ceul and PI to SCEL and subsequently ligated into the modified mouse clone BAC (described above) to create the third targeting vector.
    [000230] This linkage resulted in a third targeting vector for insertion of human X, endogenous sequences at the K light chain site, which includes, from 5' to 3', 5' of the mouse homology arm containing the 23 kb of endogenous mouse 5' gene sequence K Site, an I to Cell site, a 5' Frt site, a neomycin cassette, a 3' DRF site, a 123 kb fragment containing the first 12 hVÀ, gene segments, a kb fragment containing the 1, 1, 2, 3, and 7 gene segments, a PI to SCEL site, and a "homology arm containing the 28 kb mouse gene sequence, including the endogenous mouse gene Ck, and Eki EK3' 3 and additional downstream (3' ) mouse gene sequence of EK3' (Figure 4B, 12/4 to K Target vector) Homologous recombination with this third target vector created a modified mouse Light chain K site containing 12 hVÀ gene segments and four hJÀ gene segments operatively linked to the endogenous mouse gene CK dongo, which, after recombination, leads to the formation of a chimeric human À mouse / light K chain. A mini-site À . human with an integrated human k light chain sequence.
    [000231] Similarly, two additional targeting vectors similar to those designed to make an initial insertion of human gene segments into the endogenous À light chain K site (Figure 4B, 12/1 to K and Vectors 12/4 to K Targeting) were designed to progressively insert human light A gene strand segments using uniquely constructed targeting vectors containing contiguous human A and K gene sequences. These vectors were constructed by targeting to include one to 23 kb of human K gene sequence naturally located between the human Vk 4 to 1 and JÀ 1 gene segments. This human K gene sequence was specifically positioned in these two additional vectors targeting between human V2, and human JÀ, gene segments (Figure 4B, 12(K) and 1 to K 12 (K) 4 to K Target vector).
    [000232] Both vectors containing the human K genome target sequence were made using the modified RP11 method to 729g4 clone BAC described above (figure 6). This modified BAC clone was targeted with a spectinomycin selection cassette flanked by NotI and AsiSI restriction sites (figure 6, top left). Homologous recombination with spectinomycin cassette resulted in a dual-target BAC 729g4 clone study which includes, from 5' to 3', a I to Ceul site, a 5' Frt site, a neomycin cassette, a 3' DRF site, a 123 kb fragment containing the first 12 segments of the hVÀ± gene, a NotI site about 200 µm downstream (3') with the sequence of the nonomer segment hVÀ±3 to 1 gene, a spectinomycin cassette and an AsiSI site. A separate human BAC clone containing the human K sequence (CTD at 2366j12) was targeted twice independently to design restriction site at locations between hVÀ.4 to 1 and hJÀ 1 gene segments to allow subsequent cloning of an α fragment 23 kb for binding with hVÀgene segments contained in the modified double target 729g4 BAC clone (Figure 6, right).
    [000233] In summary, the BAC clone 2366j12 is about 132 kb in size and contains hVÀ gene segments. 1 to 6, 1 to 5, 2 to 4, 7 to 3, 5 to 2, 4 to 1, the human K gene sequence downstream of the VK gene segments, hJÀ gene segments 1 to 5, the Hck and about 20 kb of additional human K site gene sequence. This clone was initially targeted by a targeting vector that contains a hygromycin cassette flanked by the DRF site and a NotI site downstream (3') of the 3' end of the Frt site. The target sequence homology arms of this vector contained the human gene 5' and 3' of the VK gene segments in the BAC clone such that, after homologous recombination with that target vector, the VK gene segments were deleted and a NotI site was manipulated by a 133 downstream of the hVÀ.4 a 1 gene segment (Figure 6, right). This modified 2366j12 BAC clone was independently targeted with two targeting vectors at the 3' end to eliminate segments Hj to K with a chloroamphenicol gene cassette that also contained either an hJÀ gene 1 segment, a PI to SCEL site and an AsiSI site or from a human gene fragment containing four segments of the hJÀ gene (supra), a P1 to SCEL site and an AsiSI site (Figure 6, right). The homology arms for these two similar targeting vectors contained the 5' and 3' sequence of the hJÀ gene segments. Homologous recombination with these vectors according to the segmentation and modified 2366j12 BAC clone produced a double to target 2366j12 clone which includes, from 5' to 3', a 'DRF site, a hygromycin cassette, the 3' 5 Frt site , a Notl site, 22800 for a human K site gene fragment containing the intergenic region between the V À 4 to 1 and JO gene segments, or a hJÀ 1 gene segment or a human À gene fragment containing hJÀ 1, JA2, JÀ 3 and JÀ 7, a PI site to SCEL and a chloroamphenicol cassette (figure 6, right). Two final targeting vectors to make the two additional modifications were performed by two ligation steps with the double target clones 729g4 and 2366j12.
    The double target clones 729g4 and 2366j12 were digested with NotI and AsiSI producing a fragment containing neomycin cassette and hVÀ gene segments. and another fragment containing the gene fragment 23 kb from the human K site containing the intergenic region between the VK4 a 1 and the JO gene segments, or a hal gene segment or a gene fragment containing hJÀ 1, JÀ 2, JÀ 3 JÀ 7 and gene segments, the local PI -SCEL and chloroamphenicol cassette, respectively. Ligation of these fragments generated two BAC clones that contain unique 5' to 3' the hVÀ, gene segments, the human K gene sequence between the Vk 4 to 1 and JO gene segments, or an hJÀ A gene segment or from a gene fragment containing hJÀ .1, JÀ 2, JÀ 3 and JÀ 7 gene segments, a PI site to SCEL, and a chloroamphenicol cassette (Figure 6, below). These new BAC clones were then digested with 1 to Ceul and PI to SCEL to release the unique fragments containing the upstream neomycin cassette and the contiguous human sequences A and K and ligated into a modified mouse BAC 302g12 clone that contained from 5' for 3' mouse gene sequence 5' of endogenous Site K, an I to Ceul site, a 5' Frt site, a neomycin cassette, a DRF 3' site, hVÀ gene segments. (3 to 12 to 3 to 1), a NotI site 200 per downstream of VK3 to 1, 23 Kb of human K sequence naturally found between human Vk 4 to 1 and Jo gene segments, or a gene segment hJÀ 1 or a genome fragment that contains hJÀ 1, JÀ 2, JÀ 3 and JÀ 7 gene segments, the mouse Exi, the mouse gene Ck and EK3' (Figure 4, 12hV2, the Vidic a hJÀ 1 and 12hVÀ. to VKJÀ to 4hJÀ Vector targets). Homologous recombination with both of these segmentation vectors created two separate modified mouse light chain K Site containing 12 gene segments, sequence hVÀ. K from the human gene, and any one of the two or four hJÀ gene segments operably linked to the endogenous mouse CK gene, which, upon recombination, leads to the formation of a chimeric human/mouse K light chain. Example III Further Engineering of Human VÀ Gene Segments Into a Human À Light Chain Mini-Site
    [000235] Additional hVÀ gene segments were added independently for each of the initial modifications described in Example 2, using similar target vectors and methods (Figure 5A, +16 ak Target vector and Figure 5B, Vector K +16 a de segmentation).
    [000236] The introduction of 16 additional segments of human Vk genes. Upstream arms (5’ ) homology used in the segmentation vector construct for adding additional 16 hV À . gene segments for the modified light chain locus described in Example 2 of the mouse gene sequence contained 5' of either the endogenous K or À-chain site of light. The 3' homology arms were the same for all vectors and contained human gene target sequences overlaid with the 5' end of the human À, the sequence of modifications as described in Example 2.
    [000237] In summary, two targeting vectors were designed to introduce an additional 16 hVÀ, gene segments modified to the mouse light chain sites described in Example 2 (Figure 5A and 5B, +16 to À or +16 to x Target vector). A 172 kb DNA fragment from human BAC clone RP11 to 761113 (Invitrogen) containing 21 consecutive hVÀde cluster A gene segments was fabricated according to a 5' arm that contains 5' mouse gene sequence homology , either to the endogenous K or À, light chain site and a 3' arm containing human À gene sequence homology. The 5' mouse K or k homology arms used in these targeting constructs were the same 5' homology arms described in Example 2 (Figure 5A and 5B). The 3' of the homology arm included a 53,057 overlapping human sequence A gene corresponding to the 5' terminal equihVÀ lens of the 123 kb fragment of human A gene sequence described in Example 2. These two targeting vectors included, from 5' to 3', 5' mouse homology arm containing either the 23 kb gene sequence 5' from the endogenous mouse K site light chain or the 24 kb mouse gene sequence 5' from the endogenous À , light chain site, 5' Frt site, a hygromycin cassette, a 3' Frt site and 171,457 pile of human k gene sequence containing 21 consecutive hV to 53 kb gene segments, which overlap the end. 5' of human À, the sequence described in Example 3 and serves as the 3' of the homology arm for this targeting construct (Figure 5A and 5B, +16 to À . or +16 to K Targeting Vectors). Homologous recombination with these segmentation vectors created independently of the modified mouse K and light chain site each hVÀ28 contains gene segments and a gene segment hJÀ .1 operatively linked to endogenous constant mouse genes (or CK CK2), which after the recombination, leads to the formation of a chimeric light chain À
    [000238] In a similar fashion, the vector K+16 to Targeting was also used to introduce the additional 16 hVÀ gene segments for the other initial modifications described in Example 2, which incorporated multiple hJÀ gene segments with and without an integrated sequence of human K (Figure 4B). Homologous recombination with this target vector at the endogenous mouse K site containing the other initial modifications created mouse K site light chain containing 28 gene segments and hVÀ hJÀ 1, 2, 3 and 7 gene segments, with and without a gene sequence human Vk to Jk gene operably linked to the endogenous mouse CK gene, which, after recombination, leads to the formation of a chimeric ka ic light chain. [00241] The introduction of 12 additional human gene segments V à . Additional hVÀ gene segments were added independently for each of the above-described modifications using similar target vectors and methods. The final locus structure resulting from homologous recombination with targeting vectors containing the additional hVÀ gene segments. are shown in Figure 7A and 7B.
    [000239] In summary, a target vector was designed for the introduction of 12 additional hVÀ gene segments to the modified mouse K and À light chain site described above (Figure 5A and 5B, +12 to À or 12 to K Vector targets) . A 93,674 per DNA fragment from human BAC clone RP11 to 22118 (Invitrogen) containing 12 consecutive gene segments hVÀdo cluster B was designed with a 5' homology arm containing 5' mouse gene sequence to either endogenous mouse K or to light chain site and a 3' arm containing human k gene sequence homology. The 5' homology arms used in this targeting construct were the same 5' homology arms used for the addition of 16 hVÀgene segments described above, (Figure 5A and 5B). The 3' of the homology arm was engineered to a PI site to SCEL at 3431 by 5' of the human VÀ gene segment 3 to 29P contained in a 27468 per fragment of the human A gene BAC clone sequence RP11 to 761I13. This P1 site to SCEL served as an attachment point to join the 94 kb fragment of human additional sequence to the a 27 kb fragment of human À sequence that overlaps with the 5' end of the human À sequence in the above modification, using o +16 to À . or +16 to x Vector targets (Figure 5A and 5B). These two targeting vectors included, from 5' to 3', a "homology arm containing either the 23 kb mouse gene sequence 5' 5 of the endogenous K light chain site or the 24 kb of gene sequence from mouse 5' of the endogenous À light chain site, a 5' Frt site, a neomycin cassette, a 3' DRF site and by 121,188 of the human À gene sequence containing 16 hVÀ gene segments and a PI site the SCEL, 27 kb from which it overlaps with the 5' end of human À, the insertion sequence of 16 hVÀ addition gene segments, and serves as the 3' homology arm for this targeting construct (Figure 5A and 5B, +12 ak or 12 a K Target vector.) Homologous recombination with these independently generated segmentation vectors modified from the mouse and K À light chain site containing 40 segments of the gene J and human hVÀ. of constant endogenous mice (CI (or CÀ 0.2) which, after recombination, leads to the formation of a chimeric light chain (bottom of figure 5A and 5B).
    [000240] In a similar fashion, the vector x+12 to Targeting was also used to introduce 12 segments of the hVÀ gene. additional to the other initial modifications that incorporate hVÀ into various segments of the hJÀ gene with and without an integrated human K sequence (Figure 4B). Homologous recombination with this target vector at the endogenous mouse K site containing the other modifications created a light chain K Site mouse containing 40 gene segments and hVÀ. hJÀ 1, 2, 3 and 7 gene segments, with and without a human gene Vk to Jk sequence operably linked to the endogenous CK mouse gene, which, after recombination, leads to the formation of a chimeric k a ic light chain. Example IV Identification of Target ES Cells Carrying the Human A Light Chain Gene Segments
    [000241] Target DNA BAC made according to the Examples above was used to electroporate mouse ES cells to create the modified ES cells to generate human chimeric mice expressing À light chain gene segments. ES cells containing an insert of unrearranged human light chain gene segments were identified by a quantitative TaqMan® assay. Specific sets of primers and probes were designed for human insertion to associated sequences and selection cassettes (allele gain, GOA), loss of endogenous mouse sequences and any selection cassettes (allele loss, LOA) and retention of mouse follow-up sequences (allele retention, AR). For each additional insertion of two human sequences, additional sets of primers and probes were used to confirm the presence of the additional human À sequences, as well as the above sets of primers and probes used to confirm retention of the pre-labeled human sequences. Table 1 shows the primers and associated probes used in quantitative PCR assays. Table 2 presents the combinations used to confirm the insertion of each human section to the light chain gene segments in ES cell clones.
    ES cells bearing the human k light chain gene segments are optionally transfected with a construct expressing FLP in order to remove the Frfed neomycin cassette introduced by inserting the targeting construct containing human VK5a gene segments 52 to Vk1 to 40 (Figure 5A and 5B). Neomycin cassette can optionally be removed by mating to mice expressing the FLP recombinase (eg US 6,774,279). Optionally, the neomycin cassette is retained in mice.




    Example V Generation of mice expressing human-to-human light chains from an endogenous light chain site
    [000243] The target ES cells described above were used as donor ES cells and an 8-stage mouse embryo was introduced by the VELOCALCAMUNDONGO ® method (see, for example, US Patent No. 7,294,754 and Poueymirou et al. ( 2007) FO generation mice that are essentially fully derived from ES target gene donor cells allowing immediate phenotypic Nature Biotech analyses.25 (1) :91 to 99. VELOCALMICE ® (FO mice fully derived from ES donor cell) independently having human gene segments were identified by genotyping using a modification of the allele assay (hVÀ lenzuela et al., supra) that detected the presence of the unique human à gene segments (supra). Use of k : light chain from mice carrying human À light chain gene segments .
    [000244] Mice homozygous for each of three successive hVÀ gene segment insertions with a single hJÀ gene segment (Figure 5B) and mice homozygous for a first insertion of hVÀ gene segments. with any one gene segment or hJÀ four human gene segments, including a human JÀVk the jic gene sequence (Figure 4B) were analyzed for K and λ light chain expression of splenocytes using flow cytometry.
    [000245] In summary, spleens were harvested from groups of mice (ranging between three and seven animals per group) and ground using glass slides. Following red blood cell (RBC) lysis with ACK lysis buffer (Lonza Walkersville), splenocytes were stained with fluorescent antibody-conjugated dyes specific for mouse CD19 (Clone 1D3; BD Biosciences), mouse CD3 (17A2; Biolegend), mouse IGIC (187.1; BD Biosciences) and mouse IGK (RML at 42; Biolegend). Data were acquired using a BDTM LSR II flow cytometer (BD Biosciences) and analyzed using FLOWJOTM software (Tree Star, Inc.). Table 3 shows the mean percentage hVÀ lores of B cells (CD19 +), K of the light chain (CD19 + 1 gx IgkTh and À light chain (CD19 + Igicigk) expression observed in splenocytes from groups of animals with each genetic modification.
    [000246] In a similar experiment, the spleen B cell contents of mice compartment homozygous for a first insertion of 12 hVÀ. and four hJÀ gene segments including a human Vk to Jk gene sequence operably linked to the mouse CK gene (lower part of Figure 4B) and the mice homozygous for 40 hVÀ. and an hJÀ gene segment (lower part of Fig. 5B or upper part of Figure 7B) were analyzed for expression and IGÀ IGK using flow cytometry (as described above). Figure 8A shows IGK and IGIC expression in CD19+ B cells from a representative mouse from each group. The number of CD19 + B cells per spleen cells was also recorded for each mouse (Figure 8B).
    [000247] In another experiment, the B cell contents of the spleen and bone marrow compartments of homozygous mice, by 40 hVÀ. and four segments of hJÀ genes including a human Vk to Jk gene sequence operably linked to the mouse CK gene (lower part of Figure 7B) were analyzed for progression through B cell development by various cell surface flow cytometry markers.
    [000248] In summary, two groups (N = 3 each, 9 to 12 weeks of age, male and female) wild type and mice homozygous for 40 hVÀ. and four hJÀ gene segments including a human Vk to Jk gene sequence operably linked to the mouse CK gene were sacrificed and the spleens and bone marrow were harvested. Bone marrow was harvested from femurs by washing with complete RPMI medium (RPMI medium supplemented with fetal calf serum, sodium pyruhvate, Hepes, 2 to mercaptoethanol, non-essential amino acids, and gentamicin). RBCs from spleen and bone marrow preparations were lysed with ACK lysis buffer (Lonza Walkersville), followed by washing with complete RPMI medium. 1x106 cells were incubated with anti-mouse CD16/CD32 antibody (2.4G2, BD Biosciences) on ice for 10 minutes, followed by labeling with a selected antibody panel for 30 min on ice.
    [000249] bone marrow panel: anti-mouse FITC to CD43 (1B11, BioLegend), PE aca kit (2B8, BioLegend), PeCy7 to IgM (11/41, eBioscience), PerCP to Cy5.5 to IgD (11th 26c.2a, BioLegend), the APC to B220 (RA3 to 6B2, eBioscience), the APC to H7 to CD19 (ID3, BD) and Pacific Blue to CD3 (17A2, BioLegend).
    [000250] Bone marrow and spleen: anti-mouse FITC to IGÀ (187.1, BD), PE to Ig À . (RML to 42, BioLegend), PeCy7 to IgM (11/41, eBioscience), PerCP to Cy5.5 to IgD (11 to 26c.2a, BioLegend), Pacific Blue to CD3 (17A2, BioLegend), APC to B220 (RA3 to 6B2, eBioscience), APC to H7 to CD19 (ID3, BD).
    [000251] Following staining, cells were washed and fixed in 2% formalin solution. Acquisition data was performed on a FACSCANTOIITM flow cytometer (BD Biosciences) and analyzed with FLOWJOTM software (Tree Star, Inc.). FIGs. 9A to 9D show the results for the spleen compartment of a representative mouse from each group. FIGs. 10A to 10E show the results for the bone marrow compartment of a representative mouse from each group. Table 4 shows the mean percentage values of B cells (CD19 +), K of the light chain (CD19 + Igielg2T), and A , of light chain (CD19 + IgiCIgk +) expression observed in splenocytes from groups of animals with various modifications genetics. Table 5 shows the mean percentages of B cells (CD194), mature B cells (B220hilgM +), immature B cells (B220IntIgM +), immature B cells expressing K light chain (B220intIgM + IGIC +) and immature B cells expressing To the light chain (IGÀ B220intIgM +, +) in wild-type bone marrow and mice homozygous for 40 hVÀ and four hJÀ . gene segments, including a human V A to JÀ gene sequence operably linked to the Mouse Ck gene. This experiment was repeated with additional groups of mice described above and demonstrated similar results (data not shown).
    The use of the human hVÀ gene in mice carrying the human light chain gene segments.
    [000252] Mice heterozygous for a first insertion of human sequences, (hV 3 to 12 to , hVÀ .3 to 1 and hJÀ 1, figure 5B) and homozygous for a third insertion of human sequences (hVÀ,5 a 52 to hVÀ 3 to 1 and NM, Figure 5B) the use of the light chain gene by reverse transcriptase polymerase chain reaction (RT to PCR) using RNA isolated from splenocytes were analyzed for human À.
    [000253] In summary, the spleens were harvested and perfused with 10 mL of RPMI 1640 (Sigma) with 5% HI to FBS in sterile disposable bags. Each bag containing a single spleen was then placed in a STOMACHERTM (Seward) and homogenized at medium setting for 30 seconds. Homogenized spleens were filtered through a 12:7 cell filter and then pelleted with a centrifuge (1000 rpm for 10 minutes) and red blood cells were lysed in BD PHARM LYSETM (BD Biosciences) for three minutes. Splenocytes were diluted with RPMI medium to 1640 and again centrifuged, followed by resuspension in 1 ml PBS (Irvine Scientific). RNA was isolated from pelleted splenocytes using standard techniques known in the art.
    [000254] RT to PCR was performed on RNA from splenocytes using specific primers for human gene segments hVÀ. and the mouse of the CK gene (Table 6). PCR products were gel purified and cloned into pCR2.1 to TOPO TA vector (Invitrogen) and sequenced with primers M13 Forward (GTAAAACGAC GGCAG; SEQ ID NO: 55) and M13 Reverse (CAGGAAACAG CTATGAC; SEQ ID NO: 56) , located within the vector in the locus flanking the cloning locus. Eighty-four total clones derived from the human À² first and third sequence inserts were sequenced to determine hVÀ gene utilization (Table 7). The nucleotide sequence of the hVÀ hJÀ a,1 to MCK junction by selected RT to PCR clones is shown in Figure 11.
    [000255] In a similar fashion, mice homozygous for a human third insert light À chain gene sequences (ie, 40 hVÀ gene segments and four hJÀ gene segments including a human VK to JÀ gene sequence, bottom of figure 7B). operationally linked to the endogenous mouse CK gene were analyzed for human use k light chain gene by RT to PCR using RNA isolated from splenocytes (as described above). The human A light chain gene segment use for selected 26 RT to PCR clones are shown in Table 8. The nucleotide sequence of the hVÀ junction. a hJÀ MCK a selected for RT a PCR of clones is shown in Figure 12.
    [000256] In a similar fashion, mice homozygous for a first human insertion to the light chain gene segments (12 hv to gene segments, and hJ11, figure 4A and figure 5A) operatively linked to the endogenous C2 mouse two genes were analyzed for human À the use of the light chain gene by RT to PCR using RNA isolated from splenocytes (as described above). The specific primers for hVÀ gene segments. (Table 6) were paired with one of two specific primers for the mouse CK2 gene; C2 2 to 1 (SEQ ID NO: 104) or CK2 to 2 (SEQ ID NO: 105).
    [000257] The rearranged hVÀMultiple gene segments for HK1 were observed from the RT-PCR clones of human light-bearing mice gene segments at the endogenous mouse À light chain site. The nucleotide sequence of the hVÀ hJÀ aa mCÀ2 junction by RT to PCR of selected clones is shown in Figure 13.



    [000258] Figure 11 shows the sequence of the hVÀ junction, the hal to MCÀ by RT to PCR from mouse clones carrying an insertion of the first and third segments of the hVÀ genes. with a single hVA gene segment. The sequences shown in Figure 11 illustrate the rearrangements involving the single different hVÀ, with hal gene segments recombined to the Mouse Ck gene. Heterozygous mice carrying a single endogenous K-site modification containing 12 hVÀ, gene and hal segments and homozygous mice carrying two endogenous modified K-site containing 40 hVÀe hJÀ 1 gene segments were both capable of producing human À gene segments operably linked to the gene Mouse Ck and produce B cells that express human A light chains. These rearrangements demonstrate that the chimeric locus were able to independently rearrange human A into multiple gene segments, independent B cells in these mice. Furthermore, these modifications to the endogenous light K chain site do not render any of the hVÀ gene segments. inoperable or prevent the multiple hVÀ chimeric recombination site and one hJÀ gene segment (JÀ 1) during B cell development, as evidenced by 16 different hVÀ gene segments that were observed to reorganize with hJÀ 1 (Table 7). Furthermore, these mice produced functional antibodies containing the human Vk segments rearranged to the JÀ gene operably linked to mouse CK genes as part of the endogenous immunoglobulin light chain repertoire.
    [000259] Figure 12 shows the junction sequence hVÀ to hJÀ to MCÀ for a selection of RT to PCR from clones of mice homozygous for 40 hVÀ, and four gene segments including a human hJÀ genomic sequence À sequences shown in Figure 12 illustrate other rearrangements involving multiple unique hVÀ segments different genes, spanning the entire chimeric locus, with multiple hJÀ segments different genes rearranged and operatively linked to the Mouse Ck gene. Homozygous mice carrying modified endogenous K site containing 40 hVÀ. and four hJÀ gene segments were also able to produce human k gene segments operably linked to the mouse CK gene and produce B cells expressing human À light chains. These rearrangements further demonstrate that stages of all chimeric loci were able to independently rearrange human k gene segments into multiple independent B cells in these mice. Furthermore, these additional modifications to the endogenous K light chain site demonstrate that insertion of each human À gene segments does not render any of the hVÀ and/or JJ gene segments inoperable or prevent the chimeric site from recombining the hVÀ. and JÀ gene segments during B cell development, as evidenced by 12 different hVÀ gene segments that were observed to rearrange with all four hJÀ gene segments (Table 8) from the selected clone 26 RT to PCR. Furthermore, these mice also produced functional human antibodies containing VÀ to JÀ gene segments operatively linked to mouse CK regions as part of the endogenous immunoglobulin light repertoire chain.
    [000260] Figure 13 shows the sequence of the hVÀ junction. to hJÀ to mCk2 by three individuals RT to PCR from mouse clones homozygous for 12 gene segments and hVÀ. hJÀ 1. The sequences shown in Figure 13 illustrate other rearrangements involving the unique hVÀ segments. different genes, covering the entire length of the first insertion, with hJÀ 1 rearranged and operatively linked to the mouse gene CK2 (2D1 = V À 2 to 8JÀ 1; 2D9 = VK3 to 10JÀ 1; 3E15 = V À A clone demonstrates the rearrangement unproductive due to additions of N at hVÀ to hJÀ , junction (2D1, figure 13).This is not uncommon in V(D)J recombination, as the junction of gene segments during recombination has been shown to be imprecise. an unproductive recombinant present in the light chain repertoire of these mice, this demonstrates that the genetic mechanism contributing to junctional diversity between antibody genes is functioning normally in these mice and that it leads to a repertoire of antibodies containing light chains with greater diversity.
    [000261] Endogenous mice carriers homozygous modified at the À site containing 12 segments of genes hVÀ and hJÀ 1 were also able to produce human À gene segments operably linked to an endogenous mouse CÀ gene and produce B cells that express reverse light À chains that contain the mouse hVÀ-linked regions CÀ À regions. These rearrangements further demonstrate that the light chain segments of human À genes placed in the other light chain locus (ie, the locus ) were able to independently rearrange human gene segments in multiple independent B cells in these mice. Furthermore, modifications at the endogenous k light chain site demonstrate that insertion of human À gene segments does not render any of the hVÀ and/or hJÀ 1 gene segments inoperable or prevent the chimeric site from recombining the hVÀ and hJÀ 1 gene segments B cell genes during development. In addition, these mice also produced functional human antibodies containing VÀ to JÀ gene segments operably linked to a mouse CÀ region as part of the endogenous immunoglobulin light chain repertoire.
    [000262] As shown in this example, mice carrying human À light chain gene segments at the endogenous K site and at the À light chain site are able to rearrange the human light À chain gene segments and expressing them in the context of a Mouse Ck and/or CÀ region as part of the normal mouse antibody repertoire because a functional light chain is required for multiple checkpoints in developing B cells in both the spleen and bone marrow. B cell initials (eg, pre, pro to B cells and transition) demonstrate a normal phenotype in these mice compared to wild-type littermates (Figures 9D, 10A and 10B). A small deficit in bone marrow and peripheral B cell populations was observed, which can be attributed to an elimination of a sub-a set of immature B-cell auto-reactivity and/or a sub-optimal association of human light chain with To the mouse heavy chain. However, the use of Igk / IgÀ observed in these mice demonstrates a situation that is more similar to human light chain expression than that seen in mice. Example VI Breeding Mice Expressing Human Light Chains From an Endogenous Light Chain Site
    [000263] To optimize the use of human gene segments in a site of the endogenous mouse light chain, mice with unrearranged human gene segments are bred to another mouse containing a deletion at the site of the opposite endogenous light chain ( or K or À ). For example, human gene segments positioned at the endogenous K site would be the only functional light chain gene segments present in a mouse that also performed a deletion at the endogenous À, light chain site. Thus, the progeny obtained would express only human light chains as described in the preceding examples. Creation is carried out using standard techniques recognized in the art and, alternatively, by commercial companies, eg The Jackson Labocamundongory. Mouse strains carrying human À, light chain gene segments at the endogenous K site a deletion of the endogenous À light chain site are screened for the presence of unique reverse a chimeric (mouse to human) À light chains and absence of endogenous mouse À , light chains.
    [000264] Mice with an unrearranged human À light chain site are also bred with mice that contain a replacement of the endogenous mouse heavy chain site Variable gene with the human heavy chain site of the Variable gene (see US 6,596,541 , Regeneron Pharmaceuticals, the genetically modified VELOCALMMUNE ® mouse). The VELOCALMMUNE ® mouse includes, in part, a genome comprising human heavy chain variable regions operatively linked to the mouse's endogenous constant region site such that the mouse produces antibodies comprising a human heavy chain variable region and a mouse constant region of the heavy chain, in response to antigenic stimulation. DNA encoding antibody heavy chain variable regions can be isolated and operably linked to DNA encoding human heavy chain constant regions. The DNA can then be expressed in a cell capable of expressing the fully human antibody heavy chain. After creating an appropriate schedule, mice bearing a replacement of the endogenous mouse heavy chain site with the human heavy chain site and an unrearranged human À light chain site at the endogenous K light chain site is obtained. Containing somatically mutated antibodies human variable heavy chain and human À² regions, the light chain variable regions can be isolated by immunization with an antigen of interest. Example VII Generation of Mouse Antibodies Expressing Human Heavy Chains and Human Light Chains
    [000265] After breeding that mice contain unrearranged human light chain K site from various strains that contain desired modifications and deletions of another endogenous Ig site (as described above), selected mice are immunized with an antigen of interest.
    [000266] In general, a VELOCALMMUNE ® mouse containing one of the only human rearranged germline light chain regions is challenged with an antigen and lymphatic cells (such as B cells) are retrieved from the animals' serum. The cells can be lymphatic fused with a myeloma cell line to prepare immortal hybridoma cell lines, and these hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies containing human heavy chain and human light chain A that are specific for the antigen used for immunization. DNA encoding the heavy chain variable regions and the À, light chains can be isolated and linked to the desirable isotypic heavy chain and light chain constant regions. Due to the presence of the additional ha gene segments, compared to the local endogenous À mouse, the diversity of the light chain repertoire is dramatically increased and confers greater diversity of the antigen-specific repertoire after immunization. The resulting cloned antibody sequences can subsequently be produced in a cell, such as a CHO cell. Alternatively, DNA encoding chimeric antigen-specific antibodies or light and heavy chain variable domains can be isolated directly from lymphocyte-specific antigens (eg, B cells).
    [000267] Initially, high affinity chimeric antibodies are isolated with a human Variable region and a mouse constant region. As described above, antibodies are characterized and selected for desirable characteristics, including selectivity, affinity, epitope, etc. The mouse constant regions are replaced by means of a desired human constant region to generate the fully human antibody containing a somatically heavy chain mutated human and a human k light chain derived from an unrearranged human À-light chain site of the present invention. Suitable human constant regions include, for example, wild type or modified IgG1, IgG2, IgG3 or IgG4.
    权利要求:
    Claims (13)
    [0001]
    1. Method for preparing an antibody that binds to an antigen of interest, characterized in that it comprises: (a) exposing a mouse to the antigen of interest, in which the mouse is determined to comprise: a plurality of gene segments in the region unrearranged human immunoglobulin À light chain À (hVÀ) variable and at least one unrearranged human immunoglobulin light chain (hJÀ) gene segment contiguous with an unrearranged human immunoglobulin k light chain constant region nucleic acid sequence mouse; (b) obtain one or more mouse B lymphocytes from (a), wherein one or more B lymphocytes form the antibody that binds to the antigen of interest; and (c) identifying a nucleic acid sequence encoding an antibody immunoglobulin light chain, wherein the immunoglobulin light chain comprises a human immunoglobulin light chain À variable domain and a mouse immunoglobulin K constant domain; and (d) employing the nucleic acid sequence of (c) with a human immunoglobulin light chain constant region nucleic acid sequence to make a human antibody that binds to the antigen of interest.
    [0002]
    2. Method according to claim 1, characterized in that it lacks a functional mouse gene Jk and/or mouse Vk.
    [0003]
    3. Method according to claim 1, characterized in that the plurality of unrearranged hVÀ gene segments are at least 12 gene segments, at least 28 gene segments, or at least 40 gene segments.
    [0004]
    4. Method according to claim 1, characterized in that at least one gene segment hJÀ is selected from the group consisting of JÀ1, JÀ2, JÀ3, JÀ7, and a combination thereof.
    [0005]
    5. Method according to claim 1, characterized in that an endogenous locus of the mouse immunoglobulin A light chain is deleted in whole or in part.
    [0006]
    6. Method according to claim 1, characterized in that the nucleic acid sequence of the mouse immunoglobulin k light chain constant region is in an endogenous mouse immunoglobulin k light chain locus.
    [0007]
    7. Method according to claim 1, characterized in that about 10% to about 45% of mouse B cells express an antibody that comprises an immunoglobulin À light chain that comprises a light chain variable domain (VÀ ) from human immunoglobulin and a mouse immunoglobulin light chain k (Ck) constant domain.
    [0008]
    8. Method according to claim 7, characterized in that the human VÀ domain is derived from a rearranged hVÀhJÀ nucleic acid sequence selected from the group consisting of VÀ3-1/JÀ1, VÀ3-1/JÀ7, VÀ4- 3/JÀ1, VÀ4-3/JÀ7, VÀ2-8/JÀ1, VÀ3-9/JÀ1, VÀ3-10/JÀ1, VÀ3-10/JÀ3, VÀ3-10/JÀ7, VÀ2-14/JÀ1, VÀ3-19/ J1, 2-23/J1, V3-25/J1, V1-40/J1, V1-40/J2, V1-40/J3, V1-40/J7, V7-43/J1, V7-43/J3, GO1-44/JÀ1, GO1-44/JÀ7, GO5-45/JÀ1, GO5-45/JÀ2, GO5-45/JÀ7, GO7-46/JÀ1, GO7-46/JÀ2, GO7-46/JÀ7, GO9- 49/JÀ1, VÀ9-49/JÀ2, VÀ9-49/JÀ7 and VÀ1-51/JÀ1.
    [0009]
    9. Method according to claim 1, characterized in that it further comprises a human Vk-Jk intergenic region from a human immunoglobulin k light chain locus, wherein the human Vk-Jk intergenic region is contiguous with the nucleic acid sequence VA and nucleic acid sequence J.
    [0010]
    10. Method according to claim 9, characterized in that the human Vk-Jk intergenic region is placed between the VA nucleic acid sequence, and the J nucleic acid sequence.
    [0011]
    11. Method for preparing an antibody that binds to an antigen of interest, characterized in that it comprises: (a) exposing a mouse to the antigen of interest, wherein the mouse is determined to comprise: (i) at least 12 a at least 40 unrearranged human immunoglobulin Á light chain variable region gene segments and at least one human JA gene segment in an endogenous mouse immunoglobulin light chain locus; (ii) an intergenic human Vk-Jk sequence situated between the at least 12 to at least 40 human immunoglobulin light chain variable region gene segments and at least one ALREADY human nucleic acid sequence; wherein the mouse expresses an antibody comprising an immunoglobulin light chain comprising a human VA domain , a human JÁ domain and a mouse Ck domain; (b) obtain one or more mouse B lymphocytes from (a), wherein one or more B lymphocytes form the antibody that binds to the in antigen. have; and (c) identifying a nucleic acid sequence encoding an antibody immunoglobulin light chain, wherein the immunoglobulin light chain comprises a human immunoglobulin light chain variable domain Á and a mouse immunoglobulin K constant domain; and (d) employing the nucleic acid sequence of (c) with a human immunoglobulin light chain constant region nucleic acid sequence to make a human antibody that binds to the antigen of interest.
    [0012]
    12. Method according to any one of claims 1 to 11, characterized by the fact that the mouse has a k use to an À use in a ratio of about 1:1.
    [0013]
    13. Method according to claim 12, characterized in that a population of immature B cells obtained from mouse bone marrow exhibits a k utilization to an À utilization in the ratio of about 1:1.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012032991B1|2021-08-10|METHOD FOR PREPARING AN ANTIBODY THAT BINDS TO AN ANTIGEN OF INTEREST
    AU2015275243B2|2017-06-15|Mice expressing a light chain with human lambda variable and mouse constant regions
    AU2011271043B8|2016-01-21|Mice expressing a light chain with human lambda variable and mouse constant regions
    同族专利:
    公开号 | 公开日
    US10266803B2|2019-04-23|
    EP2480676B1|2016-04-06|
    EP2480675B1|2016-04-06|
    ES2575223T3|2016-06-27|
    IL255179A|2018-06-28|
    US20160060359A1|2016-03-03|
    KR101991234B1|2019-06-20|
    NZ605758A|2014-08-29|
    CN104404050B|2018-06-08|
    US20130323790A1|2013-12-05|
    IL244450A|2017-11-30|
    BR122020013427B1|2021-08-03|
    NZ626979A|2015-05-29|
    HK1183321A1|2013-12-20|
    US20150351371A1|2015-12-10|
    IL264634A|2019-09-26|
    US20150246976A1|2015-09-03|
    KR102193823B1|2020-12-22|
    US20140137275A1|2014-05-15|
    ES2721749T3|2019-08-05|
    IL259965D0|2018-07-31|
    DK2905338T3|2017-11-06|
    AU2011271046A1|2013-01-31|
    SI2480675T1|2016-08-31|
    US20120070861A1|2012-03-22|
    CA2803864A1|2011-12-29|
    KR102266097B1|2021-06-18|
    PT2905338T|2017-11-10|
    TR201905992T4|2019-05-21|
    AU2011271043A9|2015-10-01|
    CN103068993B|2016-01-06|
    US20150173331A1|2015-06-25|
    CN104404050A|2015-03-11|
    US20150320023A1|2015-11-12|
    US9206261B2|2015-12-08|
    KR102118565B1|2020-06-03|
    WO2011163311A1|2011-12-29|
    MX347318B|2017-04-21|
    SG10201504324UA|2015-07-30|
    US9029628B2|2015-05-12|
    ME02444B|2016-09-20|
    US20150176002A1|2015-06-25|
    IL223719A|2016-10-31|
    JP2018023403A|2018-02-15|
    US20150089680A1|2015-03-26|
    LT2480675T|2016-10-10|
    US20190153384A1|2019-05-23|
    KR102001430B1|2019-07-18|
    RS55042B1|2016-12-30|
    SI2480676T1|2016-10-28|
    HUE030285T2|2017-05-29|
    EP2568049B1|2016-04-13|
    RU2601297C2|2016-10-27|
    SI2568049T1|2016-10-28|
    KR20210134424A|2021-11-09|
    PT3034608T|2019-05-28|
    SMT201600229B|2016-08-31|
    US20120073004A1|2012-03-22|
    CY1117692T1|2017-05-17|
    BR112012032991A2|2015-10-06|
    JP6009441B2|2016-10-19|
    SG186390A1|2013-01-30|
    AU2011271046B2|2015-10-01|
    KR20190014578A|2019-02-12|
    US9206262B2|2015-12-08|
    US9850462B2|2017-12-26|
    US20170258059A1|2017-09-14|
    US20200239837A1|2020-07-30|
    US20160057979A1|2016-03-03|
    IL244450D0|2016-04-21|
    HK1168384A1|2012-12-28|
    IL269078A|2021-05-31|
    MX347322B|2017-04-21|
    IL223720A|2017-05-29|
    HRP20190807T1|2019-08-23|
    US9844212B2|2017-12-19|
    JP6545773B2|2019-07-17|
    RS56589B1|2018-02-28|
    EP3205726A1|2017-08-16|
    US20170107484A1|2017-04-20|
    US20190203171A1|2019-07-04|
    PL2905338T3|2018-01-31|
    KR102059909B1|2019-12-27|
    SMT201600213B|2016-08-31|
    ME02440B|2016-09-20|
    HUE044001T2|2019-09-30|
    JP6073441B2|2017-02-01|
    US9540452B2|2017-01-10|
    MX336344B|2016-01-15|
    JP2017012204A|2017-01-19|
    KR101945352B1|2019-02-07|
    HRP20160865T1|2016-10-07|
    AU2011271043B2|2015-10-01|
    BR112012033248A2|2017-11-28|
    RU2590594C2|2016-07-10|
    JP2016010417A|2016-01-21|
    MX2012015300A|2013-05-01|
    US9334333B2|2016-05-10|
    KR102320944B1|2021-11-04|
    SI3034608T1|2019-06-28|
    DK2480676T3|2016-06-20|
    KR20190014576A|2019-02-12|
    RU2016119423A|2018-11-07|
    CA2804311C|2017-09-12|
    US9394373B2|2016-07-19|
    HUE029691T2|2017-03-28|
    SI2905338T1|2017-12-29|
    US9226484B2|2016-01-05|
    AU2011271043A1|2013-01-31|
    ZA201404601B|2016-02-24|
    ZA201300063B|2014-09-25|
    EP2905338B8|2018-01-24|
    MY157477A|2016-06-15|
    JP5988969B2|2016-09-07|
    US9150662B2|2015-10-06|
    HK1226766A1|2017-10-06|
    RS54891B1|2016-10-31|
    JP2013532974A|2013-08-22|
    CY1119478T1|2018-03-07|
    JP2020128440A|2020-08-27|
    NZ605751A|2014-10-31|
    CA2804311A1|2011-12-29|
    RS55037B1|2016-12-30|
    NO2905338T3|2017-12-30|
    JP2020062061A|2020-04-23|
    US20180064078A1|2018-03-08|
    US20150173332A1|2015-06-25|
    CN104342455B|2017-05-31|
    KR20190073584A|2019-06-26|
    KR20130121814A|2013-11-06|
    LT2568049T|2016-10-10|
    KR101934852B1|2019-01-04|
    ZA201404600B|2015-09-30|
    CA2803864C|2017-05-16|
    IL282872D0|2021-06-30|
    DK3034608T3|2019-05-06|
    EP2568049A1|2013-03-13|
    KR20180135997A|2018-12-21|
    KR20190142436A|2019-12-26|
    ME03386B|2020-01-20|
    EP3034608B1|2019-01-30|
    KR20190049932A|2019-05-09|
    US9012717B2|2015-04-21|
    KR20200064166A|2020-06-05|
    AU2011271043A8|2016-01-21|
    CY1118126T1|2017-06-28|
    NZ627119A|2015-05-29|
    EP2905338B1|2017-08-02|
    CN103068993A|2013-04-24|
    PL2480676T3|2016-10-31|
    JP2017006152A|2017-01-12|
    ES2570131T3|2016-05-17|
    US20130326647A1|2013-12-05|
    RS58736B1|2019-06-28|
    DK2568049T3|2016-08-01|
    IL269078D0|2019-11-28|
    RU2013102596A|2014-07-27|
    JP2018201527A|2018-12-27|
    PT2480675T|2016-07-11|
    BR112012032991A8|2020-09-29|
    JP6341972B2|2018-06-13|
    CN104342455A|2015-02-11|
    ZA201300062B|2014-09-25|
    MY165287A|2018-03-21|
    JP2013531501A|2013-08-08|
    ES2576928T3|2016-07-12|
    PL2568049T3|2017-03-31|
    RU2724736C2|2020-06-25|
    JP2018201528A|2018-12-27|
    KR102211911B1|2021-02-05|
    KR101970944B1|2019-04-23|
    PL3034608T3|2019-08-30|
    EP3456832A1|2019-03-20|
    KR20180135996A|2018-12-21|
    JP2021061863A|2021-04-22|
    ZA201506598B|2017-03-29|
    PT2480676E|2016-06-09|
    US9035128B2|2015-05-19|
    EP2905338A1|2015-08-12|
    HK1170766A1|2013-03-08|
    US9399683B2|2016-07-26|
    PL2480675T3|2017-03-31|
    PT2568049T|2016-07-11|
    ES2646052T3|2017-12-11|
    CN103068994B|2016-01-20|
    RU2016119423A3|2019-11-19|
    ME02442B|2016-09-20|
    DK2480675T3|2016-08-01|
    KR101975884B1|2019-05-10|
    LT3034608T|2019-05-27|
    LT2905338T|2017-12-27|
    SG186391A1|2013-01-30|
    EP2480675A1|2012-08-01|
    HUE029692T2|2017-03-28|
    HUE036597T2|2018-07-30|
    JP6963542B2|2021-11-10|
    CY1117537T1|2017-04-26|
    US9066502B2|2015-06-30|
    SG10201504568YA|2015-07-30|
    US20150246977A1|2015-09-03|
    JP6243384B2|2017-12-06|
    KR20130027555A|2013-03-15|
    ME02902B|2018-04-20|
    IL247386A|2017-07-31|
    WO2011163314A1|2011-12-29|
    RU2013102595A|2014-07-27|
    JP2016010415A|2016-01-21|
    US9163092B2|2015-10-20|
    KR20200143511A|2020-12-23|
    MX2012015298A|2013-05-01|
    EP2480676A1|2012-08-01|
    EP3034608A1|2016-06-22|
    NZ707200A|2016-04-29|
    US9006511B2|2015-04-14|
    CN103068994A|2013-04-24|
    SMT201600212B|2016-08-31|
    IL255179D0|2017-12-31|
    KR20210013376A|2021-02-03|
    JP2019033765A|2019-03-07|
    HRP20171666T1|2017-12-15|
    HRP20160497T1|2016-07-15|
    HRP20160794T1|2016-08-12|
    NZ707198A|2016-04-29|
    KR20210073609A|2021-06-18|
    MX348942B|2017-07-04|
    US9206263B2|2015-12-08|
    IL259965A|2019-02-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB8823869D0|1988-10-12|1988-11-16|Medical Res Council|Production of antibodies|
    US6673986B1|1990-01-12|2004-01-06|Abgenix, Inc.|Generation of xenogeneic antibodies|
    US5770429A|1990-08-29|1998-06-23|Genpharm International, Inc.|Transgenic non-human animals capable of producing heterologous antibodies|
    US7041871B1|1995-10-10|2006-05-09|Genpharm International, Inc.|Transgenic non-human animals capable of producing heterologous antibodies|
    ES2315612T3|1991-04-10|2009-04-01|The Scripps Research Institute|GENOTECAS OF HETERODYMERIC RECEPTORS USING PHAGEMIDS.|
    AU669124B2|1991-09-18|1996-05-30|Kyowa Hakko Kirin Co., Ltd.|Process for producing humanized chimera antibody|
    IL109168D0|1993-04-01|1994-06-24|Univ Columbia|A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs|
    US6632976B1|1995-08-29|2003-10-14|Kirin Beer Kabushiki Kaisha|Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene|
    EP2305027B1|1996-12-03|2014-07-02|Amgen Fremont Inc.|Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom|
    US6774279B2|1997-05-30|2004-08-10|Carnegie Institution Of Washington|Use of FLP recombinase in mice|
    GB9823930D0|1998-11-03|1998-12-30|Babraham Inst|Murine expression of human ig locus|
    RU2262511C2|2000-05-18|2005-10-20|Джапан Тобакко, Инк.|Humanized monoclonal antibody raised against ailim, co-stimulating molecule for signal transfer and its pharmaceutical applying|
    US6586251B2|2000-10-31|2003-07-01|Regeneron Pharmaceuticals, Inc.|Methods of modifying eukaryotic cells|
    US6596541B2|2000-10-31|2003-07-22|Regeneron Pharmaceuticals, Inc.|Methods of modifying eukaryotic cells|
    JP3523245B1|2000-11-30|2004-04-26|メダレックス，インコーポレーテッド|Transgenic chromosome-introduced rodents for the production of human antibodies|
    GB0031284D0|2000-12-21|2001-01-31|Ks Biomedix Ltd|High affinity antibodies|
    JP4115281B2|2001-05-11|2008-07-09|キリンファーマ株式会社|Human artificial chromosome containing human antibody λ light chain gene, and non-human animal containing the human artificial chromosome capable of offspring transmission|
    GB0115256D0|2001-06-21|2001-08-15|Babraham Inst|Mouse light chain locus|
    DK1461442T3|2001-11-30|2017-12-04|Amgen Fremont Inc|Transgenic animals with human Ig lambda light chain genes|
    US20030217171A1|2002-05-17|2003-11-20|Von Stuermer Wolfgang R.|Self-replicating and self-installing software apparatus|
    EP1644417B1|2003-07-15|2014-04-30|Therapeutic Human Polyclonals, Inc.|Humanized immunoglobulin loci|
    CN1605628A|2003-09-03|2005-04-13|中国疾病预防控制中心病毒病预防控制所|Human source anti-hepatitis A virus gene engineering antibody from CHO cell|
    DK1773885T3|2004-08-05|2010-08-16|Genentech Inc|Humanized anti-c-met antagonists|
    CA2827654C|2004-10-19|2019-04-02|Regeneron Pharmaceuticals, Inc.|Method for generating an animal homozygous for a genetic modification|
    EP1831257B9|2004-12-29|2011-05-04|Yuhan Corporation|Humanized antibody specific for tumor necrosis factor-alpha|
    US7910798B2|2006-03-31|2011-03-22|Medarex, Inc.|Transgenic animals expressing chimeric antibodies for use in preparing human antibodies|
    JP2010501165A|2006-08-22|2010-01-21|ジーツーインフラメイションプロプライエタリーリミテッド|Antibody production method|
    CA2664343C|2006-10-02|2016-04-26|Regeneron Pharmaceuticals, Inc.|High affinity human antibodies to human il-4 receptor|
    US7864492B2|2006-10-31|2011-01-04|Siemens Industry, Inc.|Systems and methods for arc fault detection|
    DE102007045897A1|2007-09-26|2009-04-09|Carl Zeiss Microimaging Gmbh|Method for the microscopic three-dimensional imaging of a sample|
    CA2721231C|2008-04-14|2015-10-06|Innovative Targeting Solutions Inc.|Sequence diversity generation in immunoglobulins|
    US20110123527A1|2008-05-23|2011-05-26|Hiroaki Shizuya|Method of generating single vl domain antibodies in transgenic animals|
    CA3038954A1|2008-09-30|2010-04-08|Ablexis, Llc|Non-human mammals for the production of chimeric antibodies|
    SG172176A1|2008-12-18|2011-07-28|Univ Erasmus Medical Ct|Non-human transgenic animals expressing humanised antibodies and use therof|
    EP2517557B1|2009-07-08|2016-04-13|Kymab Limited|Animal models and therapeutic molecules|
    WO2011158009A1|2010-06-17|2011-12-22|Kymab Limited|Animal models and therapeutic molecules|
    KR102283195B1|2010-02-08|2021-07-29|리제너론 파마슈티칼스 인코포레이티드|Common light chain mouse|
    MY165287A|2010-06-22|2018-03-21|Regeneron Pharma|Mice expressing a light chain with human lambda variable and mouse constant regions|US6596541B2|2000-10-31|2003-07-22|Regeneron Pharmaceuticals, Inc.|Methods of modifying eukaryotic cells|
    US20050144655A1|2000-10-31|2005-06-30|Economides Aris N.|Methods of modifying eukaryotic cells|
    CA3038954A1|2008-09-30|2010-04-08|Ablexis, Llc|Non-human mammals for the production of chimeric antibodies|
    EP2517557B1|2009-07-08|2016-04-13|Kymab Limited|Animal models and therapeutic molecules|
    US20120204278A1|2009-07-08|2012-08-09|Kymab Limited|Animal models and therapeutic molecules|
    KR102283195B1|2010-02-08|2021-07-29|리제너론 파마슈티칼스 인코포레이티드|Common light chain mouse|
    US9796788B2|2010-02-08|2017-10-24|Regeneron Pharmaceuticals, Inc.|Mice expressing a limited immunoglobulin light chain repertoire|
    JP6529957B2|2013-03-13|2019-06-12|リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ．|Mice Expressing Limited Immunoglobulin Light Chain Repertoire|
    US20130045492A1|2010-02-08|2013-02-21|Regeneron Pharmaceuticals, Inc.|Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain|
    CA3006800A1|2010-03-31|2011-10-06|Ablexis, Llc|Genetic engineering of non-human animals for the production of chimeric antibodies|
    MY165287A|2010-06-22|2018-03-21|Regeneron Pharma|Mice expressing a light chain with human lambda variable and mouse constant regions|
    US10793829B2|2010-07-26|2020-10-06|Trianni, Inc.|Transgenic mammals and methods of use thereof|
    US10662256B2|2010-07-26|2020-05-26|Trianni, Inc.|Transgenic mammals and methods of use thereof|
    JP6482757B2|2010-07-26|2019-03-13|トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ．|Transgenic animals and methods of use|
    WO2012018764A1|2010-08-02|2012-02-09|Regeneron Pharmaceuticals, Inc.|Mice that make binding proteins comprising vl domains|
    HUE047278T2|2011-08-05|2020-04-28|Regeneron Pharma|Humanized universal light chain mice|
    EP3128009B1|2011-09-19|2020-07-29|Kymab Limited|Antibodies, variable domains & chains tailored for human use|
    WO2013041845A2|2011-09-19|2013-03-28|Kymab Limited|Animals, repertoires & methods|
    EP2761008A1|2011-09-26|2014-08-06|Kymab Limited|Chimaeric surrogate light chainscomprising human vpreb|
    MX356429B|2011-12-20|2018-05-29|Regeneron Pharma|Humanized light chain mice.|
    CN105722387B|2013-09-18|2020-01-17|瑞泽恩制药公司|Histidine engineered light chain antibodies and genetically modified non-human animals for production thereof|
    ES2849349T3|2012-03-16|2021-08-17|Regeneron Pharma|Histidine Engineered Light Chain Antibodies and Genetically Modified Rodents for Generation|
    EP2825037B1|2012-03-16|2019-05-01|Regeneron Pharmaceuticals, Inc.|Rodents expressing ph-sensitive immunoglobulin sequences|
    US20140013456A1|2012-03-16|2014-01-09|Regeneron Pharmaceuticals, Inc.|Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same|
    CA2865644A1|2012-03-16|2013-09-19|Regeneron Pharmaceuticals, Inc.|Mice that produce antigen-binding proteins with ph-dependent binding characteristics|
    US9445581B2|2012-03-28|2016-09-20|Kymab Limited|Animal models and therapeutic molecules|
    US10251377B2|2012-03-28|2019-04-09|Kymab Limited|Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies|
    US9253965B2|2012-03-28|2016-02-09|Kymab Limited|Animal models and therapeutic molecules|
    EP2831245A1|2012-03-28|2015-02-04|Kymab Limited|Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies|
    GB2502127A|2012-05-17|2013-11-20|Kymab Ltd|Multivalent antibodies and in vivo methods for their production|
    RU2017114166A|2013-02-20|2019-01-29|Регенерон Фармасьютикалс, Инк.|NON-HUMAN ANIMALS WITH MODIFIED SEQUENCES OF HEAVY IMMUNOGLOBULIN CHAINS|
    WO2014141189A1|2013-03-14|2014-09-18|Erasmus University Medical Center|Transgenic non-human mammal for antibody production|
    US9788534B2|2013-03-18|2017-10-17|Kymab Limited|Animal models and therapeutic molecules|
    US9783618B2|2013-05-01|2017-10-10|Kymab Limited|Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics|
    US20150033369A1|2013-05-02|2015-01-29|Kymab Limited|Animals, repertoires & methods|
    US9783593B2|2013-05-02|2017-10-10|Kymab Limited|Antibodies, variable domains and chains tailored for human use|
    AU2014330922A1|2013-10-01|2016-03-03|Kymab Limited|Animal models and therapeutic molecules|
    US20170101460A1|2014-01-10|2017-04-13|Allermabs Co. Ltd.|Transgenic animals capable of producing humanized ige at much higher levels than mouse ige|
    KR20160131118A|2014-03-21|2016-11-15|리제너론 파마슈티칼스 인코포레이티드|Vl antigen binding proteins exhibiting distinct binding characteristics|
    RU2016141307A3|2014-03-21|2018-10-24|
    PT3151921T|2014-06-06|2019-11-21|Squibb Bristol Myers Co|Antibodies against glucocorticoid-induced tumor necrosis factor receptorand uses thereof|
    MX2017003640A|2014-09-19|2017-10-31|Regeneron Pharma|Chimeric antigen receptors.|
    WO2016054598A2|2014-10-03|2016-04-07|Massachusetts Institute Of Technology|Antibodies that bind ebola glycoprotein and uses thereof|
    MX2017006624A|2014-11-21|2017-08-21|Bristol-Myers Squibb Company|Antibodies against cd73 and uses thereof.|
    JP6738348B2|2014-12-19|2020-08-12|リジェネサンス ベスローテン フェンノートシャップ|Antibodies that bind to human C6 and uses thereof|
    AU2016214399B2|2015-02-05|2020-01-16|Basf Se|Solar power plant comprising a first heat transfer circuit and a second heat transfer circuit|
    US11111314B2|2015-03-19|2021-09-07|Regeneron Pharmaceuticals, Inc.|Non-human animals that select for light chain variable regions that bind antigen|
    SG10202008304TA|2015-05-29|2020-10-29|Squibb Bristol Myers Co|Antibodies against ox40 and uses thereof|
    MX2017016502A|2015-06-29|2018-03-12|Univ Rockefeller|Antibodies to cd40 with enhanced agonist activity.|
    CN105274116B|2015-10-21|2020-09-29|重庆金迈博生物科技有限公司|Nucleic acid molecule for preparing humanized antibody and application thereof|
    JP6983776B2|2015-11-19|2021-12-17|ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company|Antibodies to Glucocorticoid-Induced Tumor Necrosis Factor Receptorand Their Use|
    EP3384030A4|2015-12-03|2019-07-03|Trianni, Inc.|Enhanced immunoglobulin diversity|
    JP6929877B2|2016-02-04|2021-09-01|トリアニ・インコーポレイテッドＴｒｉａｎｎｉ， Ｉｎｃ．|Enhancement of immunoglobulin production|
    EA201891983A8|2016-03-04|2020-05-28|Бристол-Майерс Сквибб Компани|COMBINED THERAPY BY ANTIBODIES TO CD73|
    CA3016534A1|2016-03-04|2017-09-08|The Rockefeller University|Antibodies to cd40 with enhanced agonist activity|
    US10968279B2|2016-05-09|2021-04-06|Bristol-Myers Squibb Company|TL1A antibodies and uses thereof|
    SG11201809552SA|2016-05-20|2018-11-29|Regeneron Pharma|Methods for breaking immunological tolerance using multiple guide rnas|
    CN113907043A|2016-06-03|2022-01-11|瑞泽恩制药公司|Non-human animals expressing exogenous terminal deoxynucleotidyl transferase|
    WO2017214089A1|2016-06-06|2017-12-14|Regeneron Pharmaceuticals, Inc.|Non-human animals expressing antibodies with human lambda light chains|
    US20170372142A1|2016-06-27|2017-12-28|Facebook, Inc.|Systems and methods for identifying matching content|
    US10077306B2|2016-07-14|2018-09-18|Bristol-Myers Squibb Company|Antibodies against TIM3 and uses thereof|
    WO2018044970A1|2016-08-31|2018-03-08|University Of Rochester|Human monoclonal antibodies to human endogenous retrovirus k envelopeand uses thereof|
    CU20200105A7|2016-10-13|2021-08-06|Massachusetts Inst Technology|ANTIBODIES THAT BIND THE ZIKA VIRUS ENVELOPE PROTEIN|
    RU2757665C2|2016-11-04|2021-10-20|Регенерон Фармасьютикалс, Инк.|Animals other than humans with constructed locus of light lambda chain of immunoglobulin|
    MX2019009117A|2017-02-17|2019-09-13|Squibb Bristol Myers Co|Antibodies to alpha-synuclein and uses thereof.|
    TW201843173A|2017-04-07|2018-12-16|美商必治妥美雅史谷比公司|Anti-icos agonist antibodies and uses thereof|
    RU2020118699A|2017-12-05|2022-01-10|Регенерон Фармасьютикалз, Инк.|NON-HUMAN ANIMALS HAVING AN ENGINEERED LAMBDA IMMUNOGLOBULIN LIGHT CHAIN AND THEIR USE|
    JP2021511026A|2018-01-12|2021-05-06|ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ|Antibodies to TIM3 and its use|
    CA3093407A1|2018-03-23|2019-09-26|Bristol-Myers Squibb Company|Antibodies against mica and/or micb and uses thereof|
    CA3093995A1|2018-03-24|2019-10-03|Regeneron Pharmaceuticals, Inc.|Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof|
    AU2019242586A1|2018-03-26|2020-10-01|Regeneron Pharmaceuticals, Inc.|Humanized rodents for testing therapeutic agents|
    EP3801010A4|2018-06-08|2022-02-23|Crystal Bioscience Inc|Transgenic animal for producing diversified antibodies that have the same light chain i|
    CA3103646A1|2018-06-14|2019-12-19|Regeneron Pharmaceuticals, Inc.|Non-human animals capable of engineered dh-dh rearrangement and uses thereof|
    CN112969929A|2018-10-26|2021-06-15|日本汽车能源株式会社|Battery control device|
    TW202033555A|2018-11-16|2020-09-16|美商必治妥美雅史谷比公司|Anti-nkg2a antibodies and uses thereof|
    US11008395B2|2019-01-22|2021-05-18|Bristol Myers-Squibb Company|Antibodies against IL-7R alpha subunit and uses thereof|
    CA3127153A1|2019-02-22|2020-08-27|Regeneron Pharmaceuticals, Inc.|Rodents having genetically modified sodium channels and methods of use thereof|
    SG11202111258TA|2019-06-05|2021-11-29|Regeneron Pharma|Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof|
    CA3144958A1|2019-07-01|2021-01-07|Trianni, Inc.|Transgenic mammals and methods of use thereof|
    WO2021113297A1|2019-12-02|2021-06-10|Regeneron Pharmaceuticals, Inc.|Peptide-mhc ii protein constructs and uses thereof|
    WO2021231732A1|2020-05-15|2021-11-18|Bristol-Myers Squibb Company|Antibodies to garp|
    WO2021261620A1|2020-06-25|2021-12-30|주식회사 휴맵|Heterozygous transgenic animal|
    法律状态:
    2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2019-06-04| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2019-12-17| B07G| Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]|
    2020-03-31| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-03-02| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|
    2021-06-22| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-08-10| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
    优先权:
    申请号 | 申请日 | 专利标题
    US35731710P| true| 2010-06-22|2010-06-22|
    US35731410P| true| 2010-06-22|2010-06-22|
    US61/357,317|2010-06-22|
    US61/357,314|2010-06-22|
    PCT/US2011/041370|WO2011163314A1|2010-06-22|2011-06-22|Hybrid light chain mice|BR122020013427-5A| BR122020013427B1|2010-06-22|2011-06-22|METHOD FOR MAKING A MOUSE, A CELL OR TISSUE DERIVED FROM A MOUSE AND A HYBRIDOMA|
    [返回顶部]